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Chemical Investigation of Three Antarctic Marine Sponges 
 
Young Chul Park 
 
ABSTRACT 
 
This thesis describes the chemical investigation of three marine sponges from 
Antarctica and the total syntheses of natural products erebusinone (12) and its derivative, 
erebusinonamine (52).  Investigation of the yellow Antarctic marine sponge Isodictya 
setifera resulted in the isolation of two secondary metabolites, purine analog (32) and 3-
hydroxykynurenine (24).  Chemical investigation of Isodictya setifera led to the isolation 
of six secondary metabolites which included 5-methyl-2-deoxycytidine (25), uridine 
(28), 2-deoxycytidine (31), homarine (37), hydroxyquinoline (33), 3-
hydroxykynurenine (24).  The latter two compounds were found to be intermediates of 
tryptophan catabolism in crustaceans.  From the Antarctic marine sponge Isodictya 
antractica ceramide analog (39) was isolated and its chemical structure was assigned by 
a combination of spectroscopic and chemical analyses.  Stereochemistry was determined 
by modified Mosher’s method.  Erebusinone (12), a yellow pigment isolated from the 
Antarctic marine sponge Isodictya erinacea has been implicated in molt inhibition and 
mortality against the Antarctic crustacean amphipod, Orchomene plebs, possibly serving 
as a precursor of a xanthurenic acid analog.    
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3-Hydroxykynurenic acid
OH
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Erebusinonamine
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NH3Cl
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OH
(12) (52) (24)  
 
Thought to act as a 3-hydroxykynurenine 24 mimic, erebusinone (12) may be 
involved chemical defense.1 This appears to be the first example in the marine realm of 
an organism utilizing tryptophan catabolism to modulate molting as a defensive 
mechanism.  To further investigate the bioactivity and ecological role of erebusinone 
(12), the synthesis of this pigment was carried out in an overall yield of 44% involving 
seven steps which were economical and convenient. Erebusinonamine (52) was also 
similarly synthesized in eight steps with an overall yield of 45%.    
 
Reference 
1. Moon B. H.; Park Y. C.; McClintock J. B.; Baker B. J., Tetrahedron 2000, 56, 9057-
9062.     
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Chapter 1. INTRODUCTION 
 
1.1.  A Brief History of  Natural Products 
    
Natural products of terrestrial plants have been utilized for many purposes such 
as medicines, euphoria and hunting.  The use of crude natural products to treat cancer 
has a long history, recorded at least as far back as the Ebers papyrus in 1550 B. C.1   
The origin of traditional Chinese medicine also dates back to around 2500 B. C.2   With 
the origin of organic and biological chemistry in the 19th century, chemists and 
biologists began the investigation of bioactive compounds in order to identify the 
individual active ingredients from the terrestrial plants, freshwater, and marine 
organisms.   
The study bioactive plant compounds such as morphine, strychnine, atropine, 
quinine and colchicine was begun in the early 1800’s.   However, the structures of these 
secondary metabolites were not elucidated until a century.3   The invention of advanced 
instrumentation tools, such HPLC (high performance liquid chromatography) and NMR 
(nuclear magnetic resonance) spectrometers enabled the characterization of minute 
quantities of secondary metabolites such as maitotoxin and taxol.4-6    
 
1.2. Marine Natural Products Chemistry 
 
Marine organisms have been investigated by natural products chemists for the 
past 40 years.   Many of the secondary metabolites produced are both complex and quite 
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distinct from terrestrial natural products.  Marine natural products chemistry has 
evolved from being the source of a handful of chemical curiosities 20 years ago to being 
one of the most productive areas of natural products research.7-9  The oceans and seas 
have been the focus of considerable attention for their biological resources.  Marine 
organisms have evolved under markedly distinctive chemical and physical conditions 
from terrestrial plants and animals.10  Oceanic marine organisms are of scientific 
interest for two major reasons. First, they constitute a major share of the Earth’s 
biological resources.11  Second, marine organisms often possess  unique structures, 
metabolic pathways, reproductive systems, and sensory and chemical defense 
mechanisms,12,13  because they have adapted to environmental conditions which have 
high biodiversity.  Their range encompasses the cold polar Arctic and Antarctic seas at 
low temperature, the warm water tropics and the bright shallow waters to the great 
pressures of the deep ocean floor.  Yet the potential of this domain as the basis for new 
biotechnology resources such as drug discovery remains largely underexplored.   Recent 
improvements in underwater life-support systems, however, have facilitated the 
collection of organisms from previously unexplored regions of the oceans.  Many 
bioactive chemicals from the marine environment have been isolated and 
characterized.14-31  Same hold great promise for useful biotechnological applications, 
such as development of a wide range of pharmaceutical compounds, medical research 
materials, agricultural products and processes, novel energy sources and bioremediation 
techniques.32,33  With knowledge of these factors, several marine invertebrates and 
microorganism groups have been noted for their potential for new drug discovery.33,34 
Many marine invertebrates such as algae, corals, sponges and ascidians (tunicates) use 
 2
highly evolved chemical compounds for purposes such as reproduction, communication, 
and protection against predation, infection, and competition.11  These bioactive 
chemical compounds may have antibiotic, anti-inflammatory, antiviral, cytotoxic, 
antitumor or antifungal properties.  Secondary metabolites, which are not needed by the 
organism for basic or primary metabolic processes such as food digestion, energy 
storage, or metabolism, are believed to confer some evolutionary advantage because 
many marine invertebrates living in densely populated habitats are non-motile, have 
primitive immune systems, and are found symbiotic relationships with 
microorganisms.35,36   
Natural product chemists have been interested in sponge-microbe symbioses 
because of the possibility that the diverse, bioactive chemical structures found in 
sponges might be produced by microorganisms.  More natural products have been 
reported from sponges37 than from any other marine invertebrate phylum, and many of 
the most promising pharmaceuticals and agents for cell biological research were 
isolated from sponges.37   Marine sponges belong to the phylum Porifera and are 
actually simple cell aggregates, which are usually referred to as the most undeveloped 
multicellular animals.14-31 In contrast, ascidians belong to the phylum Chordata, which 
encompasses all vertebrate animals, including mammals.  As much as 40% of the cell 
mass of sponges, ascidians and other marine macroorganisms could be composed of 
prokarytic organisms.38,39 
The first isolation of a secondary metabolite from a marine organism was 
Tyrian purple (6,6’-dibromoindigotin) (1) from a marine mollusk. Identified in 1901,7,40  
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Tyrian purple (1) was also the first marine natural product to be used for commercial 
applications. 
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Tyrian Purple (1)  
The marine environment became the focus of natural products drug discovery 
research because of its relatively unexplored biodiversity compared to terrestrial 
environments.  The potential for marine natural products as pharmaceuticals was 
introduced by the pioneering work of Bergmann in 1950’s which led to the discovery of 
Ara-A (2)41 and Ara-C (3),42 the only two marine derived pharmaceuticals that are 
clinically available today. The anticancer drug cytosine arabinoside (Ara-C) (3) is used 
to treat acute myelocytic leukemia.43  The antiviral drug adenine arabonoside (Ara-A) 
(2) is used for the treatment of herpes virus infections.44,45  
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Adenine Arabinoside 
(Vidarbine)
Ara-A (2)
Cytosine Arabinoside
       (Cytarabine)
Ara-C (3)
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Both are derived from nucleosides isolated from a shallow water marine sponge 
Cryptotethya crypta collected off the coast of Florida. 
The cytotoxic macrolide bryostantin (4), isolated from the bryozoan Bugula 
neritina, was found to have anticancer activity against murine P388 lymphocytic 
leukemia in vitro cell line.46  It is now in clinical trials for the treatment of leukemias, 
lymphomas, melanoma and solid tumors.47,48   
O
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MeOOC
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OAc
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COOMe
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O
OH
OH
OH
OH
Bryostatin (4)  
 
        Another example of an important marine natural products include ecteinascidin 
743 (5), a secondary metabolite displaying strong anticancer activity, which was first 
isolated from the mangrove tunicate, Ecteinascidia turbinata in 1990.50, 51  
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Marine prostaglandins, first discovered in a gorgonian have since been isolated 
from other invertebrates and from red algae.53 Punaglandins,52 which are halogenated 
antitumor eicosanoids, were isolated from the octocoral Telesto riisei. These 
punaglandins (6, 7) are characterized by C-12 oxygen and unprecedented C-10 chlorine 
functions and inhibit L1210 leukemia cell proliferation with an IC50 values in the range 
of 0.02 µg/mL.54, 55 
O
Cl
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Punaglandin 3 (6)
O
Cl
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OAc O
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Punaglandin 4 (7)
Papuamine (8), an antifungal pentacyclic alkaloid from the marine sponge 
Haliclona sp., a thin, red, encrusting sponge, is formally derivable from a C22 
unbranched hydrocarbon and 1,3-diaminopropane and inhibits the growth of the fungus 
Trichophyton mentagrophytes.56
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Spongia tubulifera found in the Florida Keys contains two types of toxins.  The 
spongianolids, exemplified by spongianolide A-F (9,10) and kuropongin (11) are a 
series of cytotoxic sesterterpenes which display potent MCF-7 mammary tumor cell 
inhibition activity, inhibition of protein kinase C and antibiotic activity, displaying 5 
mm zones of inhibition at 100 µg/disk toward a host of antibiotic tester strains.57
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Kurospongin (11)  
Marine sponges are among the most prolific sources of diverse chemical 
compounds with therapeutic potential.  Of the more than 5000 chemical compounds 
derived from marine organisms, more than 30 percent have been isolated from 
sponges.49 
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1.3.  Antarctic Marine Natural Products 
 
The Antarctica marine benthos has diverse and abundant biological and 
ecological communities.  For 20 million years the Antarctica benthos has had physically 
unique, isolated environments and ecology. These factors provide a basis to study the 
chemical and biological interactions such as competition and predation.   Secondary 
metabolites from Antarctica have recently begun to be studied and they have been 
found to display unique biological activities such as cytotoxic, antimicrobial, antifungal, 
and antiviral properties.  This may result from unique functional roles for Antarctic 
species.58   
On the benthos of McMurdo Sound, Antarctica, sponges are found to occupy 
55% of the surface area.59  The sea star Perknaster fuscus and the amphipod Orchomene 
plebs are predominant and voracious sponge predators.  We reported that the bright 
yellow marine sponge Isodictya erinacea is a conspicuous member of the sponge 
community on the McMurdo Sound and suggested that despite a lack of physical 
protection such as spicules, I. erinacea is chemically defended against predator O. 
plebs.60,61     
Secondary metabolites, erebusinone (12), erinacine (13) were isolated from I. 
erinacea.   Erebusinone (12) displayed molt inhibition leading to increased mortality in 
the predator amphipod, Orchomene plebs, serving as the first example in the marine 
realm of molt inhibition as a chemical defense mechanism.   Erinacine (13) has shown 
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cytotoxcity (LD50 50 µg/mL) against L5178Y mouse lymphoblastoid cells and 
displayed chemical deterrence toward the sea star Perknaster fuscus. 60,61,62
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Sponges of the genus Latrunculia apicalis have been chemically studied.  
Ichthyotoxic and cytotoxic agents have been reported from the Red Sea Latrunculia 
magnifica63 and South Pacific Latrunculia species.64  Discohabdin C (14) and G (15), 
imino-quinone pigments having antibiotic and cytotoxic activity and influencing sea 
star (Perknaster fuscus) feeding behavior were isolated from the Antarctic sponge 
Latrunculia apicalis Ridley and Dendy from McMurdo Sound.65  Variolin A (16) is 
unusual cytotoxic alkaloid, has been isolated from the bright red sponge Kirkpartrickia 
variolosa.66
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Rhapsamine (17), a linear C28 polyene substituted by terminal 1,3-
diaminoglycerol groups was isolated from the Antarctic sponge Leucetta leptorhapsis 
from the Ross sea.  It was found to have potent cytotoxicity displaying LC50 of 1.8 µM 
in the KB nasopharyngeal cell line.67 
H2N
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N
OH
H
N
OH
H2N
Rhapsamine (17)  
Secondary metabolites, membranolide (18), 9, 11-dihydrogracillin (19) and an 
isoquinoline pigment (20) were isolated from the bright yellow Antarctic sponge 
Dendrilla membranosa.   The isoquinoline pigment, 4,5,8 trihydroxyquinoline-2-
carboxylic acid displayed antibacterial activity against the marine bacteria Vibrio 
angullarum and Beneckea harveyii B-392.68,69 
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9,11-Dihydrogracilin A (19)
OAc
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1.4. Research Objectives 
 
Antarctic marine organisms have evolved differently under markedly 
distinctive chemical and physical conditions compared to terrestrial plants and animals.  
To study its chemical and ecological relationships of marine organisms in Antarctica, 
we have investigated three marine sponges.   The benthos of McMurdo Sound is 
characterized by extensive sponge communities with spongevorous.   Previously we 
reported that the secondary metabolite, erebusinone from Isodictya erinacea has been 
implicated in molt inhibition and mortality against an Antarctic crustacean, Orchomene 
plebs, perhaps serving as precursor of a xanthurenic acid analog.61  With our previous 
metabolite profile, biological activities and ecological implications, we suggest that the 
Antarctic sponge, Isodictya setifera may have similar chemical defense mechanisms.  
To further investigate the chemical ecology of Antarctic sponges, we studied three 
Antarctic marine sponges, Isodictya erinacea, Isodictya setifera, and Isodictya 
antarctica.   We also synthesized the natural product, erebusinone (12) and its 
derivative, erebusinonamine (52). 
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Chapter 2. CHEMICAL INVESTIGATION OF ANTARCTIC 
MARINE SPONGE ISODICTYA ERINACEA 
 
2.1 Introduction 
    
The marine sponge Isodictya erinacea (Topsent, 1916) (Family Esperiopsidae)   
is a conspicuous member of the Antarctic benthos which appears to be free of predation 
despite its lack of structural protection elements such as spicules (Figure 1).   
 
Figure 1. Isodictya erinacea collected from at Erebus Bay, Ross Island, Antarctica 
(Photograph supplied by Bill J. Baker, University of South Florida) 
 
We have previously reported that I. erinacea is chemically defended against 
the major Antarctic sponge predator, the sea star Perknaster fuscus and the isolation of 
 12
secondary metabolites, erebusinone (12), erinacean (13), 1,9-dimethylguanine (21), 7-
methyladenine (22).  Erebusinone, a yellow pigment is a tryptophan catabolite and 
appears to protect the sponge from crustacean predation by inhibition of molting in 
predatory amphipods.   In the course of our continuing search for secondary metabolites 
possessing ecological and biological significance, I. erinacea has been further studied.60, 
61,70   
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2.2 Extraction and Isolation of Secondary Metabolites 
 
The chemical investigation of  Isodictya erinacea collected from Erebus Bay 
on the western coast of Ross Island, Antarctica resulted in the isolation and structure 
elucidation of two compounds, purine (23) and 3-hydroxykynurenine (24) 
 
The wet sample of Isodictya erinacea was extracted (Scheme 1) with MeOH at 
7 ˚C.    After concentration, the residue was subjected to Sephadex LH-20® column 
chromatography with MeOH/CH2Cl2 (1:1) to provide five fractions. Fraction 4 was 
subjected to C18 column chromatography with a MeOH/CH2Cl2 gradient system to give 
additional fractions.     The first fraction 8 was chromatographed on silica gel to give 4 
fractions. Fraction 11 (Scheme 1) was further chromatographed on silica gel yielding a 
purine analog (23) (68 mg, 0.0068% dry wt). Fraction 12 (104 mg) was 
chromatographed on silica gel to give 3-hydroxykynurenine (24) (13.5 mg, 0.00135% 
dry wt) (Scheme 1). 
 
 
N
N N
NCH3
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NH2
O NH2
O
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   Isodictya erinacea
1.0 Kg (frozen and wet)
1. Extraction with MeOH, 2 L X 5 times at 7 oC 
2. Filteration over C18 (8 cm X 2 cm)
20 g
Fraction 1
 0.21g
Fraction 2
   6.34g
Fraction 3
   5.71g
Fraction 5
   0.73g
Frction 6
 510 mg
LH-20 (5 cm X 60 cm), CH2Cl2/MeOH (1:1)
  C18 column (2.5 cm X 45 cm)
 1. 100 % MeOH, 2.100% CH2Cl2
Fraction 8
  374 mg
Fraction 9
  169mg
silica gel column (2.5 cm X 45 cm)
H2O/MeOH/CHCl3 (0.4:3.0:6.6)
Fraction 10
   70 mg
Fraction 11
  104 mg
Fraction 12
   152 mg
Fraction 13
   61 mg
silica gel (2.5 cm x 30 cm) 
H2O/MeOH/CH2Cl2 (0.4:3:6.6)
  Purine analog 
    23 (68 mg)
0.0068 % yield
3-Hydroxykynurenine
     24 (13.5 mg)
    0.00135% yield
silica gel (2.5 cm X 30 cm)
H2O/MeOH/CH2Cl2 (0.5:4:5.5)
Fraction 4
   1.1g
Fraction 7
487 mg
 
 
Scheme 1. Isolation of purine analog 23 and 3-hydroxykynurenine 24. 
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 2.3 Characterization of Purine analog (23) 
      
From fraction 11, purine analog 23 was obtained as a pale brown solid and 
assigned the molecular formula C8H11N5O, as deduced by HREIMS (observed m/z 
193.0959, calculated 193.0964). The 1H NMR spectrum (Figure 2) of purine analog 
(23) in DMSO-d6 contained four signals at   δ 3.36, δ 3.61, and δ 3.88 which suggested 
methyl protons bearing nitrogen and an aromatic methine at δ 8.17 with one 
exchangeable proton signal at δ 3.4. The 13C NMR spectrum (Figure 3) showed three 
methyl groups at δ 33.4, 32.2, 29.3, one methine at δ 143.6 and four quaternary carbons 
at δ 152.5, 151.3, 148.2, 106.9. 
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Figure 2. 1H NMR spectrum of purine analog (23) (500 MHz, DMSO-d6). 
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Figure 3. 13C  NMR spectrum of purine analog (23) (125 MHz, DMSO-d6). 
 
The IR spectrum of 23 showed one carbonyl stretching absorption band at 
1715 cm-1, a C=N stretching absorption band at 1641 cm-1  and  NH stretching 
absorption bands at 3303 cm-1.  The basic chemical skeleton of this purine analog (23) 
was established by a gHMBC (gradient Heteronuclear Multiple Bond Connectivity) in 
DMSO-d6   as shown in (Figure 4).  Three methyl proton signals bearing nitrogen 
revealed connectivity (Figure 5) from N-1-CH3 to C-2 (δ151.3) and C-6 (δ152.5); from 
N-3-CH3 to C-2 (δ151.3) and C-4 (δ147.6); from N-7-CH3  to C-5 (δ106.9) and C-8 
(δ143.6) and one methine proton bearing carbon signal showed HMBC three-bond 
correlations with two quaternary carbons at C-5 (δ106.9) and C-8 (δ143.6).  Table 1 
provides a summary of NMR spectroscopic data. 
 17
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Figure 4. HMBC spectrum of purine analog (23) (500 MHz, DMSO-d6). 
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Figure 5. Key gHMBC correlations observed in purine analog (23). 
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N-1-Me              3.36 (3.42)a              29.3 (27.8)a                 C2, C6
C-2                                                  151.3 (151.7)
N-3-Me              3.61 (3.66)              32.2 (30.6)                    C2, C4
C-4                                                  147.6 (147.2)
C-5                                                  106.9 (106.8)
C-6                                                  152.5 (152.2)
N-7-Me              3.88 (3.95)              33.4 (32.4)                    C5, C8
C-8                                                  143.6 (142.9)
C-8-H(1H)          8.17 (8.14)                                                   C4, C5
N-9
gHMBCposition 13C(δ)1H(δ)
Table 1. NMR data of purine analog (23) (DMSO-d6) 
               (13C, 125 MHz; 1H NMR 500 MHz)
a Chemical shifts (δ) measured in MeOH-d4 (13C, 75 MHz; 1H NMR 250 MHz)  
 
 
 
The UV spectrum of purine analog (23) showed at λmax  210 nm and 268 nm, 
which is similar to absorption properties of known compounds 1,3,7-trimethylguanine 
[UV (MeOH) λmax  213 nm and 288 nm]71 and 1,3,7-trimethylisoguanine [UV (MeOH) 
λmax  214 nm and 288 nm].72   The mass spectrum of purine analog 23 and its 1-, 3-, 
and 7- methyl derivatives have been analyzed in detail.73  In the LREIMS spectrum of 
purine analog (23) (Scheme 2), fragments at m/z 178.1 [M-NH]+ and m/z 164.1 [M-
CHO]+  were observed.   The fragments of m/z 138.1 [M-HNCNCH3]+ due to the loss 
of methyl cyanamide at [M-55]+, which then sequentially loses CO (m/z 109), HCN 
(m/z 82.1) as were reported in an N-1-methylated isoguanine purine73 as the most 
characteristic mode of decomposition of this compound.  Scheme 2 illustrates these 
fragmentations  
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Scheme 2.  Proposed fragmentations of purine analog 23. 
 
 
2.4 Characterization of 3-Hydroxykynurenine (24) 
 
3-Hydroxykynurenine (24) was obtained as a bright yellow powder 
(C10H12N2O3) and was soluble in DMSO and MeOH.  The UV absorption in MeOH 
showed λmax 234, 273, 381 nm.  The compound displayed a classic 1H NMR (Figure 6) 
pattern for a 1, 2, 3-trisubstituted aromatic ring with signals at δ7.26 (1H, dd, J = 1.2, 
8.2 Hz), δ 6.79 (1H, dd, J = 1.3, 7.5 Hz), and δ 6.45 (1H, t, J = 8.2 Hz) in MeOH-d4. 
The three aliphatic protons were observed including one methine at δ 3.98 (1H, dd, J = 
2.7, 9.0 Hz), two methylene protons at δ 3.70 (1H, dd, J = 2.5, 18.6 Hz) and δ 3.47 (1H, 
dd, J = 9.5, 18.5 Hz).  The 1H NMR spectrum of aromatic proton chemical shifts of 3-
hydroxykynurenine (24) was similar to that of erebusinone (12) (Figure 7) in MeOH-d4. 
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Figure 6. 1H NMR spectrum of 3-hydroxykynurenine (24) (250 MHz, MeOH-d4). 
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Figure 7. 1H NMR spectrum of synthetic erebusinone (12) (250 MHz, MeOH-d4). 
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The 13C NMR spectrum (Figure 8) indicated the presence of ten carbons; six 
aromatic carbons at δ 145.5, 141.6, 121.6, 117.4, 117.1, 114.6, two carbonyl carbons at 
δ 170.3 and δ 200.0 and two aliphatic carbons at δ 50.5 and δ 41.1.  The structure of 3-
hydroxykynurenine (24) was deduced by analysis 2D NMR techniques [gCOSY 
(gradient COrrelation SpectroscopY), gHSQC (gradient Heteronuclear Single 
Quantum Correlation), and gHMBC)] (Figure 9, 10). 
 
Figure 8. 13C NMR spectrum of 3-hydroxykynurenine (24) (125 MHz, DMSO-d6). 
 
In the gHSQC experiment, mutual cross-peaks were observed between the 
aromatic protons at δ 7.19 (H-1), 6.85 (H-2), 6.40 (H-4) to carbons at δ 121.6, 117.4, 
and 114.6, respectively.  Also, in the gHMBC spectrum (Figure 9) (Table 2), long range 
couplings (2JCH/ 3JCH) were observed between δ 7.12 (H-1) and C-12 (δ 200.0), C-10 (δ 
 22
145.5), C-9 (δ 141.6), C-8 (δ 117.1), and C-2 (δ 117.4) indicating the presence of the 
benzene ring (Figure 10). 
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Figure 9. gHMBC spectrum of 3-hydroxykynurenine (24) (500 MHz, DMSO-d6). 
 
 
OH
NH2
O NH2
O
OH
81
9102
4
12
6
5
11
 
Figure 10. Key gHMBC correlations observed in 3-hydroxykynurenine (24). 
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Table 2. NMR data of 3-hydroxykynurenine (24) (DMSO-d6) (13C, 125 MHz; 1H, 500 MHz)
1        7.19 (1H, d, J = 8.2 Hz)                     121.6         C12, C10, C9, C8, C2
2        6.85 (1H, d, J = 7.6 Hz)                     117.4         C10, C9, C1
3        6.70 (2H, s)                                                          C10, C8
4        6.40 (1H, t, J = 8.0 Hz)                      114.6         C10, C8
5        3.62 (1H, d, J = 7.8 Hz)                       50.5         C12, C11, C6, C7
6        3.50 (1H, dd, J = 2.3, 18.1 Hz)            41.1         C12, C5
7        3.24 (1H, dd, J = 8.6, 17.5 Hz)            41.1         C12, C5
8                                                                    117.1
9                                                                    141.6                             
10                                                                  145.5
11                                                                  170.3
12                                                                  200.0
1H (δ)a 13C(δ) gHMBC
a  1H NMR (250 MHz, MeOH-d4) δ 3.46 (1H, dd, J = 9.5, 18.5 Hz), 3.70 (1H, dd, J = 2.5, 18.7 
Hz), 3.97 (dd, J = 2.5, 9.7 Hz), 6.45 (t, J = 8.2 Hz), 6.79 (d, J = 7.5 Hz), 7.26 (d, J = 8.2 Hz)
 
The 3-hydroxykynurenine (24) displayed an optical rotation [α]25D  -47.6˚ (c = 
0.17, MeOH)  which is similar to that reported [α]25D -45˚ [(c = 0.9, MeOH)]74,75 
suggesting absolute stereochemistry at position C-5 of our isolate to be the S 
configuration.   The UV spectrum of compound 24 observed in λmax 234, 273, 381 nm 
in MeOH (pH = 7) was similar to previously reported absorption values, λmax 224, 266, 
370 nm (0.005 M HCl) from literature.74   
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Figure 11. Assigned NMR data of erebusinone61 and 3-hydroxykynurenine (MeOH-d4, 
1H NMR 250 MHz; 13C NMR, 75, 125 MHz) * 1H chemical shifts. 
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Chapter 3. CHEMICAL INVESTIGATION OF ANTARCTIC 
MARINE SPONGE ISODICTYA SETIFERA 
 
3.1 Introduction 
    
The Antarctic marine sponge Isodictya setifera Topsent (family Esperiopsidae) 
(Figure 12) has received attention due to its bioactive metabolites which were isolated 
from the sponge-associated with bacterial strain Pseudomonas aerugenosa, which 
showed strong antibacterial activity.76   Although the chemistry of the I. setifera 
sponge-associated bacterium has been reported,77,78 the secondary metabolites of the 
sponge have not been reported. 
 
Figure 12. Isodictya setifera collected from Bahia Paraiso, Palmer Station, Antartica 
(Photograph supplied by Bill J. Baker, University of South Florida). 
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3.2 Extraction and Isolation of Secondary Metabolites 
 
In continuation of our study of Isodictya setifera, sponges were collected by 
SCUBA diving at the Bahia Paraiso shipwreck on the coast near Palmer station, 
Antarctica, and  chemically studied, resulting in the isolation of six compounds, 5-
methyl-2’-deoxycytidine (25), uridine (27), 2-deoxycytidine (30), hydroxyquinoline 
(33), 3-hydroxykynurenine (24), and homarine (37). 
 
The freeze–dried sample of Isodictya setifera was exhaustively extracted with 
MeOH at room temperature (Scheme 2).   After concentration, the crude extract was 
partitioned with hexane, MeOH, H2O and BuOH. The BuOH soluble material was 
subjected to Sephadex LH-20® column chromatography (5 cm X 60 cm) with MeOH to 
provide seven fractions.   Fraction 12 was further subjected to normal phase column 
chromatography with MeOH/CH2Cl2 and CH3CN (acetonitrile)/H2O and followed by 
reversed phase HPLC with a cyano-derivatized column using a gradient CH3CN/H2O to 
give pure compounds which are 5-methyl-2’-deoxycytidine (25, 3.0 mg, 0.0007% dry 
wt), uridine (28, 2.0 mg, 0.0005% dry wt), 2’-deoxycytidine (31, 1.5 mg, 0.0003% dry 
wt), hydroxyquinoline (33, 1.8 mg, 0.0004% dry wt), 3-hydroxykynurenine (24, 1.7 
mg, 0.0004% dry wt), and homarine (37, 2.0 mg, 0.0005% dry wt). 
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   Isodictya setifera
   435g(freeze dried)
1. Extraction with MeOH (3 X 3 L)
2. Hexane/MeOH/ H2O (4:5:1)
    CH2Cl2/MeOH/ H2O (4:5:1)
    BuOH/H2O (4:1)
LH20, MeOH (2.5 X 50 cm)
Fraction 6
   85mg
Fraction 7
  130 mg
Fraction 8
  174 mg
Fraction 9
  223 mg
Fraction10
  190 mg
Fraction11
  390 mg
Fraction 12
  570 mg
Fraction 1
   9.0 g
Fraction 2
  2.3 g
Fraction 3
  6.0 g
    Fraction 4
       1.9 g
(BuOH extract)
Fraction 5
      38g
(H2O extract)(Hexane extract) (CH2Cl2/MeOH extract)
1. silica gel column (2.5 X 40 cm)
2. HPLC with reversed cyano column 
    CH3CN/H2O (from 99:1 to 80:20)
5-Methyl-2'-deoxycitidine
25, 3.0 mg (0.0007% yield)
  2'-Deoxycytidine 31
1.5 mg (0.0003% yield)
      Uridine 28
 2.0 mg (0.0005%)
3-Hydroxykynurenine 24
 1.7 mg (0.0004% yield)
   4,8-Dihydroxyquinoline
33, 1.8 mg (0.0004% yield)
       Homarine 37
2.0 mg ( 0.0005% yield)
 
Scheme 3. Isolation of nucleosides, 3-hydroxykynurenine, 4, 8-dihydroxyquinoline, and    
homarine. 
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3.3 Characterization of 5-Methyl-2’-deoxycitidine (25) 
 
The 1H NMR spectrum (Figure 13) of 5-methyl-2’-deoxycitidine (25) showed 
typical chemical shifts of nucleosides, including the presence of one olefinic methine 
group (δ 7.83),  three aliphatic mithine groups (δ 6.30. 4.42, 3.92), two aliphatic 
methylene groups (δ 3.78, 2.25) and one methyl group (δ 1.89).  The 13C NMR 
spectrum (Figure 14) showed ten carbon signals corresponding to one methyl (δ 11.3), 
two methylenes (δ 61.7, 40.0), four methines (δ 136.7, 87.4, 85.1, 71.0), and three 
quaternary carbons (δ 165.3, 151.2, 110.3) based on analysis by the gHSQC spectrum. 
 
8 7 6 5 4 3 2 PPM 
Figure 13. 1H NMR spectrum of 5-methyl-2’-deoxycitidine (25) (500 MHz, MeOH-d4). 
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Figure 14. 13C NMR spectrum of 5-methyl-2’-deoxycitidine (25) (125 MHz, MeOH-d4). 
 
First, the partial structure (a) of 5-methyl-2’-deoxycitidine was established 
using a gCOSY (Table 3) (Figure 15) experiment.  The olefinic methine at δ 7.83 (1H, s, 
H-1) showed allylic coupling with the methyl protons at δ 1.89 (3H, s, H3-7).   A second 
partial structure (b) was evidenced by the aliphatic methines at δ 6.30 (1H, t, J = 6.8 Hz, 
H-2’) coupled with neighbor methylene protons at δ 2.25 (2H, m, H-3’) which were in 
turn correlated with methines at δ 4.42 (1H, m, H-4’).  The methine at δ 4.42 (H-4’) 
showed 1, 3-correlations with methines at δ 3.92 (1H, q, J = 3.4, H-5’) and δ 2.25 (2H, 
m, H-3’). The methine at δ 3.92 (H-5’) showed correlations with one methine at δ 4.42 
(H-4’) and one methylene at δ 3.81 (1H, dd, J = 3.2, 12.5 Hz, Ha-6’) and 3.74 (1H, dd, J 
= 3.5, 11.8 Hz, Hb-6’).  The methylene protons at δ 3.81 (Ha-6’) and 3.74 (Hb-6’) 
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showed correlation with one methine at δ 3.92 (H-5’) and W-coupling with the methine 
at δ 4.42 (H-4’), completing partial structure (b). 
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Figure 15. gCOSY correlations of 25. 
 
A methine proton at δ 7.83 (H-1) showed 2JCH/3JCH correlations in the gHMBC 
spectrum (Figure 16) to C-2’ (δ 85.1), and C-7 (δ 11.3) as well as with three quaternary 
carbons C-6 (δ 110.4), C-3 (δ 151.2), and C5 (δ 165.3) supporting a pyrimidine moiety.  
The methine proton (H-2’) at δ 6.30 showed 3JCH correlation to C-1 (δ 136.7) and a 
quaternary carbon at δ 151.20 (C-3).  The methylene protons (H2-3’) showed 2JCH/3JCH 
correlations to C-2’ (δ 85.1), C-4’ (δ 71.1), and C-5’ (δ 87.6) supporting a sugar moiety.  
These data established the structure of 5-methyl-2’-deoxycytidine (25) (Figure 17). 
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Figure 16. gHMBC spectrum of 5-methyl-2’-deoxycytidine (25) (500 MHz, MeOH-d4). 
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Figure 17. Key gHMBC correlations observed in 5-methyl-2’-deoxycitidine (25).  
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Table 3 . NMR data of 5-methyl-2'-deoxycytidine (25) (MeOH-d4)
                 (13C, 125 MHz; 1H, 500 MHz)
1         7.83 (1H, s)                                  136.7 (CH)         H7            C3, C5, C6, C7, C2'
3                                                               151.2 (C)             
5                                                               165.3 (C)
6                                                               110.4 (C) 
7         1.89 (3H,s)                                      11.3 (CH3)       H1              C5, C6, C1 
2'        6.30 (1H, t, J = 6.8Hz)                    85.1 (CH)         H3'             C3, C1
3'        2.25 (2H, m)                                    40.0 (CH2)       H2', H4'      C2', C4', C5'
4'        4.42 (1H, m)                                    71.0 (CH)         H3', H5'      C2', C5'
5'        3.92 (1H, q, J = 3.4 Hz)                  87.6 (CH)         H4', H6'      C3'
6'        3.81 (1H, dd, J = 3.2,12.5 Hz)        61.7 (CH2)        H6'             C4', C5'
           3.74 (1H, dd, J = 3.5,11.8 Hz)        61.7 (CH2)        H6'             C4', C5'
position gCOSY gHMBC1H (δ) 13C (δ)
 
The chemical shifts of 5-methyl-2’-deoxycytidine (25) from the current study 
was compared with the literature and Aldrich Library of NMR spectra.79,80  All assigned 
chemical shifts by 1H NMR and gCOSY are similar those of published (Figure 18).  
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Figure 18. Assigned 1H NMR chemical shifts (δ) of 5-methyl-2-deoxycytidine 25 (500 
MHz, DMSO-d6) from the current study data, 2-deoxycytidine 2680 and thymidine 2780 
(60 MHz, D2O). 
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3.4 Characterization of Uridine (28) 
 
The 1H NMR spectrum (Figure 19) of uridine (28) is similar to that of 5-
methyl-2’-deoxycytidine (25) except for the absence of the methyl group at δ 1.89. 
 
8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 PPM 
Figure 19. The 1H NMR spectrum of uridine (28) (500 MHz, DMSO-d6). 
 
 
The 1H-1H gCOSY (Figure 20) of uridine (28) displayed 3 spin systems that 
include two olefinic methine groups (δ 7.88, 5.64), four aliphatic methine groups (δ 
5.77, 4.01, 3.95, 3.83) and contiguous with one methylene group (δ 3.61, 3.54).  The 
aliphatic methines at δ 5.77 (H-2’) coupled with its neighboring proton at δ 4.01 (H-3’), 
which was in turn correlated with δ 3.95 and with one exchangeable proton.   The 
methine at δ 3.95 (H-4’) showed further correlation (3JHH) with δ 3.83 (H-5’) and one 
exchangeable proton at δ 5.10 (H-4”).  The methine at δ 3.83 (H-5’) showed additional 
correlation (3JHH) with the methylene protons (H-6’) at δ 3.61 and 3.54 which showed 
further vicinal correlation (2JHH). 
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Figure 20. gCOSY correlation of 28. 
 
 
 
 
The 13C NMR spectrum (Figure 21) displayed nine carbon signals.  In the 
gHSQC experiment, mutual cross-peaks (1JCH) were observed between the aromatic 
protons at δ 7.88 (H-1) and 5.64 (H-6) to carbons at δ 141.4 and δ 102.4, respectively.    
Also, in the gHMBC spectrum (Figure 22), cross-peaks (2JCH/ 3JCH) were observed 
between δ 7.88 (H-1) and C-5 (δ 163.8), C-3 (δ 151.4), C-6 (δ 102.4) and C-2’ (δ 88.3) 
(Figure 23) (Table 4). 
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Figure 21. The 13C NMR spectrum of uridine (28) (500 MHz, DMSO-d6). 
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Figure 22. The gHMBC spectrum of uridine (28) (500 MHz, DMSO-d6). 
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Figure 23. Key gHMBC correlations observed in uridine (28). 
 
Table 4. NMR data of  uridine (28) (DMSO-d6) (13C, 125 MHz; 1H, 500 MHz)
1         7.88 (1H, d, J = 7.9 Hz)          141.4 (CH)      H6                    C3, C5, C6, C2'
3                                                         151.4 (C)
5                                                         163.8 (C)
6         5.64 (1H, d,  J = 8.3 Hz)         102.4 (CH)      H1                     C1
2'        5.77 (1H, d, J = 5.8 Hz)            88.3 (CH)      H3'                     C3, C1, C3'
3'        4.01 (1H, q, J = 5.4 Hz)            74.2 (CH)      H2', H4', H3"     C2', C5'
4'        3.95 (1H, q, J = 4.6 Hz)            70.5 (CH)      H3', H5', H4"     C2', C5'
5'        3.83 (1H, q, J = 3.3 Hz)            85.5 (CH)      H6', H4'
6'        3.61 (m, 1H)                              61.5 (CH)      H5', H4"    
           3.54 (m, 1H)                              61.5 (CH)     H5', H4"
3"       5.37 (1H, d, J = 5.9 Hz)                                   H3'                     C2', C3', C4'
4"       5.10 (1H, m)                                                     H4'                     C3', C4', C5'
position gCOSY gHMBC1H (δ) 13C (δ)
 
 
The natural compound uridine (28) 70 was previously isolated from Isodictya 
erinacea and characterized structure by 2D NMR.  In the current study, the isolated 
uridine 28 displayed two aromatic methines on the pyrimidine ring at δ 7.88 (H-1, J = 
7.9 Hz) and 5.64 (H-6, J = 8.3 Hz), which were identical to chemical shifts (Figure 23) 
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and coupling constant previously reported [δ 7.86 (H-1, J = 8.1 Hz) , δ 5.66 (H-6, J = 
8.1 Hz)] Comparison of reported  1H NMR data of uridine (Figure 24) showed the 
difference of chemical shifts attributed by solvent effect. 
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Figure 24. Assigned 1H NMR chemical shifts (δ) of uridine (28) (500 MHz, DMSO-d6) 
from the current study, previous reported uridine (29)70 (360 MHz, MeOH-d4) and 
uridine 3081 (60 MHz, D2O+NaOD). 
 
3.5 Characterization of 2’-Deoxycytidine (31) 
 
2’-Deoxycytidine (31) was obtained as a pale brown solid. The 1H NMR 
spectrum displayed  (Figure 25) three spin systems including two olefinic methine 
groups at δ 7.84 (1H, d, J = 8.1 Hz, H-1), and 5.63 (1H, d, J = 8.1 Hz, H-6), as well as 
four aliphatic methine groups at δ 6.14 (1H, t, J = 6.2 Hz, H-2’), 4.27 (1H, m, H-4’), 
3.77 (1H, m, H-5’) coupled to two methylene groups at δ 3.55 (2H, m, H2-6’), and 2.08 
(2H, m, H2-3’) (Figure 26). The aliphatic methines at δ 6.14 (H-2’) coupled with 
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neighboring methylene protons at δ 2.08 (H2-3’) which were correlated with two 
methines at δ 4.27 (H-4’) and 3.77 (H-5’). 
10 8 6 4 2PPM 
Figure 25. 1H NMR spectrum of 2’-deoxycytidine (31) (500 MHz, DMSO-d6). 
 
The methine at δ 4.27 (H-4’) showed 1,3 correlation (3JHH) with one methine at 
δ 3.77 (H-5’), one methylene at δ 2.08 (H-3’) and with one exchangeable proton 
attached on the position at δ 5.23 (H-4”).  
N
HO
NH2
O
HO
1
5
3
2'
3'4'
5'6'
6
N
N
O
HO
NH2
O
HO
1
2'
4'
5
5'
6
3
6'
3'
(b)
(a)
4"4"
6"
6"
 
 
Figure 26. gCOSY correlations of 31. 
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The methine at δ 3.77 (H-5’) showed correlations (3JHH) with one methine at δ 
4.27 (H-4’) and one methylene at δ 3.55 (H-6’).  The methylene protons at δ 3.55 (H2-
6’) also showed 1,3 correlation (3JHH) with one methine at δ 3.77 (H-5’) and with one 
exchangeable proton at δ 5.00 (H - 6”). 
 
The 13C NMR spectrum (Figure 27) showed nine carbons including one 
carbonyl carbon at δ 151.1.   The positions of two quaternary carbons δ 151.1 (C-3) and 
163.8 (C-5) were confirmed by correlation (2JCH/ 3JCH) with two methine protons at δ 
7.84 (H-1) and δ 5.63 (H-6) by the gHMBC experiment as shown in Figure 28.   The 
methylene protons (H-3’) on furan ring also showed correlations (2JCH/ 3JCH) (Table 5) 
with three methine carbons at δ 84.8 (C-2’), 71.1 (C-4’), and 88.0 (C-5’) (Figure 29).  
 
 
Figure 27. 13C  NMR spectrum of 2’-deoxycytidine (31) (125 MHz, DMSO-d6). 
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Figure 28. gHMBC spectrum of 2-deoxycytidine (31) (500 MHz, DMSO-d6). 
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Figure 29. Key gHMBC correlations observed in 2’-deoxycytidine (31). 
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Table 5. NMR data of 2'-deoxycytidine (31) (DMSO-d6) (13C, 125 MHz; 1H, 500 MHz)
NH2         11.27 (s, 1H)
1                7.84  (1H, d, J = 8.1 Hz)       141.2 (CH)         H6                    C12, C11
3                                                              151.1 (C)
5                                                              163.8 (C)
6                5.63  (1H, d, J = 8.1 Hz)       102.4 (CH)         H1                    C12, C2
2'               6.14  (1H, t, J = 6.1Hz)           84.8 (CH)         H3'                    C11, C2
3'               2.08  (m,2H)                            40.2 (CH2)        H2', H4'            C8, C3, C7
4'               4.27  (m, 1H)                           71.1 (CH)         H5', H3',H4"
5'               3.77  (m, 1H)                           88.0 (CH)         H4', H6'    
6'               3.55  (m, 2H)                           61.9 (CH2)        H5', H6"
4"              5.23  (br,s, 1H)                                                  H4'                          
6"              5.00  (br,s, 1H)                                                  H6'
position gCOSY gHMBC1H (δ) 13C (δ)
 
 
 
2-Deoxycytidine (31) was isolated previously from the marine sponge 
Isodictya erinacea and characterized structure by 2D NMR.70 The 1H NMR data were 
compared with the current compound (31), previous compound (32) and authentic 2-
deoxycytine (26).  In the current study (31), two aromatic methines attached to the 
pyrimidine ring of 2-deoxycytidine are found at δ 7.88 (H-1, J = 8.1 Hz) and 5.64 (H-6, 
J = 8.1 Hz), which is identical to chemical shifts and coupling constant from the 
authentic sample (Figure 30), compound (31) [ δ 7.86 (H-1, J = 8.1 Hz) , 5.66 (H-6, J = 
8.1 Hz)].71,75   The difference in chemical shifts is attributed to solvent effect. 
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Figure 30.  Assigned 1H NMR chemical shifts (δ) of natural 2-deoxycytidine (31) (500 
MHz, DMSO-d6), previously isolated 2-deoxycytidine (32) 70 (360 MHz, MeOH-d4) 
and authentic sample (26) 80 (60 MHz, D2O+NaOD). 
 
3.6 Characterization of 4, 8-Dihydroxyquinoline (33) 
 
4, 8-Dihydroxyquinoline (33) was obtained as an amorphous powder.  The 
structure elucidation, complete proton and carbon assignment were achieved by DEPT, 
gCOSY, gHSQC, and gHMBC techniques.   The 1H NMR spectrum (Figure 31) of 4,8-
dihydroxyquinoline showed chemical shifts of a classic pattern for a 1,2,3-trisubstituted 
aromatic ring at δ 7.49 (1H, dd, J = 8.0, 1.0, 1.5 Hz), 7.09 (1H, t, J = 7.8 Hz), 7.04 (1H, 
dd, J = 7.7 , 1.5 Hz)  and  pyridine moiety at δ 7.72 ( 1H, d, J = 7.2 Hz), 6.0 (1H, d, J = 
7.2 Hz).  The 13C NMR spectrum (Figure 32) of 4, 8-dihydroxyquinoline (33) displayed 
nine aromatic carbons assigned with gHSQC indicating that five methine cabons (δ 
139.4, 123.6, 115.4, 114.8, 109.2) and four quaternary carbons (δ 177.8, 147.8, 131.1, 
127.4). 
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Figure 31. 1H NMR spectrum of 4, 8-dihydroxyquinoline (33) (500 MHz, DMSO-d6). 
 
 
  
 
Figure 32. 13C NMR spectrum of 4, 8-dihydroxyquinoline (33) (125 MHz, DMSO-d6). 
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In the gHMBC spectrum (Figure 33), correlations (2JCH/ 3JCH) between proton 
and carbon were observed that the aromatic proton at H-1 (δ 7.72) to C-9 (δ 177.8), C-7 
(δ 131.1), and C-5 (δ 109.2) and H-5 (δ 6.00) to C-9 (δ 177.8), C-6 (δ 127.4), and C-1 
(δ 139.4).   A benzene moiety was evident in the gHMBC experiment (Figure 34) based 
on correlations (2JCH/ 3JCH / 4JCH) of H-2 (δ 7.50) to C-8 (δ 147.8), C-7 (δ 131.1), C-3 (δ 
123.6), and C-4 (δ 114.8) while H-3 (δ 7.09) correlated with C-8 (δ 147.8), C-7 (δ 
131.1), C-6 (δ 127.4), C-4 (δ 114.8) and C-2 (δ 115.4).    
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Figure 33. gHMBC spectrum of 4, 8-dihydroxyquinoline (33) (500 MHz, DMSO-d6). 
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Figure 34. Key gHMBC correlations observed in 4, 8-dihydroxyquinoline (33). 
 
Table 6. NMR data of 4, 8-dihydroxyquinoline (33) (DMSO-d6)
               (13C, 125 MHz; 1H, 500 MHz)
1       7.72  (1H, d, J = 7.2 Hz)              139.4  (CH)       H5            C9, C7, C6, C5
2       7.50  (1H, dd, J = 1.4, 7.9 Hz)     115.4  (CH)       H3, H4     C9, C8, C7, C3, C4
3       7.09  (1H, t, J = 7.7 Hz)               123.6  (CH)       H2, H4     C8, C7, C6, C4, C2
4       7.04  (1H, dd, J = 1.5, 7.7 Hz)     114.8  (CH)       H3, H2     C8, C7, C6, C2
5       6.00  (1H, d, J = 7.3 Hz)              109.2  (CH)       H1            C9, C6, C7, C1           
6                                                            127.4   (C)               
7                                                            131.1   (C)         
8                                                            147.8   (C)         
9                                                            177.8   (C)
gCOSY gHMBC1H (δ) 13C (δ)
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Figure 35.  Secondary metabolites of quinoline derivatives. 
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Quinoline derivatives including quinoline (34), 4,5,8-trihydroxyquinoline-2-
carboxylic acid (35) are known secondary metabolites isolated from sponges Dendrilla 
membranosa and the genus Verogia69 and are suggested to be intermediates of 
tryptophan catabolism (Figure 35). The chemical shifts of isolated 4,8-
dihydroxyquinoline (33) were compared relative to known quinoline derivatives 34, 
3569 and xanthurenic acid 36 from the Aldrich Library of NMR spectra.82 The 
quaternary C-9 at δ 177.8  in 4, 8-dihydroxyquinoline (33) showed a similar chemical 
shift with  quaternary C-9 at δ 183.6 in trihydroxyquinoline carboxylic acid (36).69 
 
3.7 Characterization of Homarine (37) 
 
Homarine (N-methyl picolinic acid) (37) was isolated as pale brown solid. The 
1H NMR spectrum of homarine (Figure 36) showed four methine groups at δ 8.72 (d, J 
= 6.0 Hz), 8.42 (t, J = 7.9 Hz), 7.90 (dd, J = 1.3, 7.8 Hz), 7.85 (t, J = 6.9 Hz) and one 
methyl group at δ 4.28 (s).     
8 6 4 2 PPM 
Figure 36. 1H NMR spectrum of homarine (37) (500 MHz, DMSO-d6). 
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        In the 13C NMR spectrum (Figure 37), the five carbons of the pyridine ring 
resonated at  δ 156.7, 145.7, 145.0, 126.9, 125.5, the quaternary carbon of carboxylic 
acid resonated at δ 161.8 and the carbon of methyl bearing nitrogen was seen at δ 46.5.     
 
 
 
Figure 37. 13C NMR spectrum of homarine (37) (125 MHz, DMSO-d6). 
 
 
In the gHMBC spectrum (Figure 38), correlations (Table 7) (2JCH/ 3JCH) from 
the aromatic proton at H-1 (δ 8.72) to C-2 (δ 145.7), C-6 (δ 156.7), C-4 (δ 125.5), C-5 
(δ 46.5), and H-2 (δ 8.42) to C-1 (δ 145.0), C-6 (δ 156.7).   H-3 (δ 7.90) correlated to C-
4 (δ 125.5), C-6 (δ 156.7), and C-7 (δ 161.8) and H-4 (δ 7.85) correlated with C-1 (δ 
145.0), and C-3 (δ 126.0), H3-5 (δ 4.26) to C-1 (δ 145.0), and C-6 (δ 156.7).  Thus, the 
structure of homarine was deduced by gCOSY and gHMBC (Figure 39). 
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Figure 38. The gHMBC spectrum of homarine (37) (500 MHz, DMSO-d6). 
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Figure 39. Key gHMBC correlations observed in homarine (37).  
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Table 7. NMR data of homarine (37)  (DMSO-d6) (13C, 125 MHz; 1H, 500 MHz)
       1     8.72 (1H, d, J = 6.0 Hz)              145.0 (CH)      H2, H4          C2, C6, C4, C5
       2     8.42 (1H, t, J = 7.9 Hz)               145.7 (CH)      H3, H4          C1, C6
       3     7.90 (1H, dd, J = 1.3, 7.8 Hz)     126.0 (CH)      H2                 C4, C6, C7
       4     7.85 (1H, t, J =  6.9 Hz)              125.5 (CH)      H1, H2, H3   C1, C3
       5     4.28 (3H, s)                                   46.5 (CH3)                           C1, C6      
       6                                                         156.7 (C)          
       7                                                         161.8 (C)
position gCOSY gHMBC1H (δ) 13C (δ)
 
Homarine was isolated from Dendrilla membranosa and showed feeding 
deterrence to the Antarctic seastar Odonataster validus83 and suggested chemical 
interactions between sponge and sea stars.83  The feeding deterrence of homarine also 
was reported Antarctic mollusk Marseniopsts mollis against seastars.84  The chemical 
shifts of homarine 37 were compared with authentic 1H NMR spectrum data (Figure 
40) from the Aldrich Library of NMR spectra85 and suggest homarine.  The difference 
in chemical shifts is attributed to solvent effect. 
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Figure 40.  Assigned 1H NMR chemical shifts (δ) of natural homarine (37) (500 MHz, 
DMSO-d6), and authentic sample (38)85 (60 MHz, D2O). 
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Chapter 4. CHEMICAL INVESTIGATION OF ANTARCTIC 
MARINE SPONGE ISODICTYA ANTARCTICA 
 
4.1 Extraction and Isolation of Secondary Metabolite 
 
The sponge Isodictya antarctica (Figure 41) was collected by SCUBA diving 
on the shipwreck Bahia Paraiso near Palmer station, Antarctica.  The freeze-dried 
sample of Isodictya antarctica was first extracted with methanol at room temperature 
(Scheme 4).       
 
Figure 41. Isodictya antarctica collected from Bahia Paraiso, Palmer Station, Antartica 
(Photograph supplied by Bill J. Baker, University of South Florida). 
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Isodictya antarctica
   141g (freeze dried)
1. Extraction with MeOH (3 X 1 L) 
2. Partition with CH2Cl2/MeOH/ H2O (500 ml/100ml/100 ml)
3. Partition with BuOH/H2O (400 ml/100 ml)
1. LH20 (2.5 cm X 50 cm), MeOH/CH2Cl2 (50:50)
2. silica gel column chromatography 
    Hexane/EtOAc (from 80:20 to 0:100)
fraction 1
EtOAc:hexane
(25:75)
1.8 g
fraction 2
EtOAc:hexane
(50:50)
560 mg
fraction 3
EtOAc:hexane
(75:25)
325 mg
fraction 4
100 % EtOAc
136 mg
fraction 5
EtOAc:MeOH
(90:10)
420 mg
CH2Cl2
extract
  5.7g
BuOH
extract
  1.7g
 H2O 
extract
  1.8g
silica gel column (2.5 cm X 45 cm) with gradient elution
fraction 6 
EtOAc:MeOH
(70:30)
627 mg
Ceramide analog
    39, 104 mg
  (0.07% yield)
 
Scheme 4. Isolation of ceramide analog (39). 
 
 
After concentration, the crude extract was partitioned with CH2Cl2, MeOH, and 
BuOH.    The CH2Cl2 soluble material was initially chromatographed on silica gel with 
gradient elution (from EtOAc/hexane to EtOAc/MeOH) to afford six fractions.  After 
combining fraction 4 and fraction 5, the resulting fraction was subjected to Sephadex 
LH-20® column chromatography and then further purified by silica gel column 
chromatography to afford a ceramide analog  (39) (104 mg, 0.07% dry wt). 
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4.2 Characterization of Ceramide analog (39) 
 
Ceramide analog (39) was obtained as a colorless amorphous solid.  The 
HRESIMS showed the [M + H]+ ion peak at m/z 664.6599 (calculated 664.6607) 
corresponding to the molecular formula C43H85NO3.  The IR spectrum showed 
absorptions at 3300 cm-1 for a hydroxyl group, 1642 cm-1 for a carbonyl.  The 1H NMR 
spectrum (Figure 42) displayed a large number of methylene groups at δ 1.28.    The 
connectivities of the aliphatic moiety were determined by gCOSY, TOCSY and the 1J 
CH connectivities were assigned by gHSQC.   
 
 
7 6 5 4 3 2 1 PPM 
Figure 42. 1H NMR spectrum of ceramide analog (39) (500 MHz, CDCl3). 
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A substructure is represented by the nonequivalent methylene proton (H-1) 
signals at δ 3.97 (dd, J = 3.8, 11.0 Hz) and 3.71 (dd, J= 3.3, 11.3 Hz), two olefinic 
proton signals at δ 5.80 (H-5) (dt, J = 7.4, 15.5 Hz) and δ 5.54 (H-4) (dd, J = 6.6, 15.6 
Hz) and two methine protons at δ 4.34 (H-3) (t, J = 5.0 Hz) and δ 3.91 (m, H-2).  The 
large coupling constants (J = 15.5, 15.6 Hz) of two methine protons at δ 5.80 and 5.54 
revealed the (E) configuration of the double bond.  The gCOSY and TOCSY (TOtal 
Correlation SpectroscopY) experiments (Figure 43) confirmed the coupling of an amide 
proton (δ 6.24) with the methine  proton at δ 3.91 (1H, m, H-2), as well as with the 
methylene proton (H2-1) signals at δ 3.97 (1H, dd, J = 3.8, 11.0), 3.71 (1H, dd, J = 3.3, 
11.3) and methine signal at δ 4.34 (1H, t, J = 5.0, H-3).  The methylene proton at δ 2.02 
(2H, m, H-6) also showed the coupling with methine signal at δ 5.54 (H-4) and 4.34 (H-
3).  Thus the 1H, 13C NMR (Figure 44), gCOSY, TOCSY, gHSQC, and gHMBC 
experiments led to confirm the partial structure (a) of ceramide analog (39). 
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Figure 43.  Key gCOSY (I) and TOCSY (II) correlations in partial structure (a).  
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Figure 44.  13C NMR spectrum of ceramide analog (39) (125 MHz, CDCl3). 
 
 
The DEPT (Distortionless Enhancement by Polarization Transfer)-135 (Figure 
45) and 90 (Figure 46) data showed five methine carbon groups at δ 134.2, 129.1, 74.2, 
54.9, 28.2 and three methyl carbons at δ 22.9, 22.8 indicating terminal isopropyl group 
and δ14.3.  The partial gHMBC data (Table 8) revealed correlations (Figure 47, 48) 
from amide proton (δ 6.24) to the methine carbons at δ 74.2 (C-3), 55.0 (C-2) and the 
methylene carbon at δ 62.4 (C-1) along with quaternary carbonyl carbon at δ 174.5 (C-
1’). 
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Figure 45. DEPT-135 spectrum of ceramide analog (39) (125 MHz, CDCl3). 
 
 
 
Figure 46. DEPT-90 spectrum of ceramide analog (39) (125 MHz, CDCl3). 
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Figure 47. Key gHMBC correlations observed in partial structure (a) of ceramide 
analog (39) (125 MHz, CDCl3). 
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Figure 48. gHMBC spectrum of ceramide analog (39) (500 MHz, CDCl3). 
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1        3.97 (1H, dd, 3.8, 11.0)    62.4 (CH2)      H2              H2, H3, NH         C2, C3
          3.71 (1H, dd, 3.3, 11.3)                           H2               H2, H3, NH
2        3.91 (1H, m)                     54.9 (CH)       H3, NH       H1, H4, H5         C4, C1'
3        4.34 (1H, t, 5.0)                74.2 (CH)       H2, H4        H1, H2, H4,        C1, C2, C4, 
                                                                                               H5, H6, NH        C5
4        5.54 (1H, dd, 6.6, 15.6)   129.1 (CH)      H3, H5        H3, H5, H6         C2, C3, C6
                                                                                               H7, NH
5        5.80 (1H, dt, 7.4, 15.5)    134.2 (CH)      H4, H6        H3, H4, H6         C3, C6
                                                                                               H7
6        2.02 (2H, m)                      32.6 (CH2)    H5, H7         H3, H4, H5         C4, C5, CH2
1'                                                174.5 (C) 
2'       2.24 (2H, t, 7.5)                37.0 (CH2)      H3'              H3', CH2              C1', C3', CH2
3'       1.60 (2H, m)                     26.0 (CH2)      H2'              H2', CH2              C1', C2', CH2 
NH    6.24 (1H, d, 7.7)                                       H2               H1, H2, H3          C1, C2, C3, 
                                                                                               H4, H5, H6          C1'
1H (δ, J, Ηz) 13C (δ) gCOSY gHMBCTOCSY
Table 8. NMR data of partial structure (a)  (CDCl3) (13C, 125 MHz; 1H, 500 MHz)
 
To determine the number of methylene carbons of ceramide analog (39), the 
natural product ceramide analog was subjected to methanolysis (Scheme 5) with 1.25 M 
HCl - MeOH for 20 hr under mild reflux and then partitioned into petroleum ether and 
MeOH layers.   
NH
O
OH
HO
n
m
HCl, MeOH
reflux
20 hr
NH2O
OH
HO
n mOCH3
NH2
OH
HO
m
Ac2O
pyridine
overnight
NHAc
OAc
AcO
m
(39) (40) (41)
(41) (42)
 
 
Scheme 5. Methanolysis and protection reactions of ceramide analog (39). 
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The MeOH layer was treated with acetic anhydride to give the protected 
compound (42).   The 1H NMR spectrum (Figure 49) of compound (40) in the 
petroleum ether layer displayed typical fatty ester moiety with methoxy proton at δ 3.59 
and provided single terminal methyl proton at δ 0.81 (3H, t, J = 6.7 Hz).  The 13C NMR 
spectrum (Figure 50) showed quaternary carbonyl carbon at δ 174.6 indicating an ester 
unit.  The molecular formula of compound 40 was determined by HREIMS as 
C25H50O2 (observed m/z 382.3804, calculated 382.3811) indicating a C24 n-nervonic 
acid moiety. 
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Figure 49. 1H NMR spectrum of methyl ester (40) (500 MHz, CDCl3). 
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Figure 50. 13C NMR spectrum of methylester 40 (125 MHz, CDCl3). 
 
 
 
The 1H NMR spectrum (Figure 51) of protected acetylated aminodiol 42 
showed three acetoxy methyl groups at δ 2.10, 2.09, 2.01 along with isopropyl unit at δ 
0.87 (6H, d, J = 6.3 Hz) and the 13C NMR spectrum (Figure 52) displayed two esters 
and one amide carbonyls at δ 171.2, 170.2, and 169.8.  The HRESIMS data of 
compound 42 displayed an ion peak at m/z 440.3372 [M + H]+ (calculated m/z 
440.3376) corresponding to the molecular formula C25H45NO5.    
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Figure 51. 1H NMR spectrum of acetylated aminodiol (42) (500 MHz, CDCl3). 
 
 
 
 
Figure 52. 13C NMR spectrum of acetylated aminodiol (42) (125 MHz, CDCl3). 
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4.3 Determination of Stereochemistry 
 
The modified Mosher’s method was used for the determination of absolute 
stereochemistry of ceramide analog (39) at C-3 using a MTPA-Cl [α-methoxy-α-
(trifluoromethyl)phenylacetyl chloride].86  The most important factor of modified 
Mosher’s method is the difference in steric bulkiness of the substitutions of the two β- 
and β’-carbons.  The steric repulsion between the phenyl group of MTPA moiety and 
the β-substitutions is essential to bring about the ∆δ of the CF3 (19F NMR) or OMe (1H 
NMR) of the (R) – and (S) - MTPA esters which is then used to determine the absolute 
stereochemistry.  However, some erroneous predictions of absolute stereochemistry 
have reported using the original Mosher’s method,87 due to the β- or β’-substituents of 
certain compounds being placed far away from the MTPA moiety or other substituents 
(γ-, δ-, ε- positions) having a greater steric interaction with the MTPA groups.86, 87  The 
modified Mosher’s method uses the same principles as the initial Mosher’s method, 
however these assigned values must meet certain conditions before the absolute 
stereochemistry can be confidently assigned.86,88  Thus, the modified method is 
generally more reliable than initial Mosher’s method.  However, there were some 
reports incorrect absolute stereochemistry assignments using this technique on 
secondary alcohols with the hydroxyl group located in crowded environments.86  If a 
molecule has a less steric crowding or hindrance around hydroxyl group, the preferred 
conformation of the MTPA ester should be obtained, and the modified Mosher’s 
method will give the correct absolute configuration.  This preferred orientation consists 
of the carbinyl proton, ester carbonyl and trifluoromethyl groups of the MTPA ester all 
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lie in the same plane (Figure 53).  In this orientation, protons (HA,B,C) of an (R) – MTPA 
ester should have an upfield 1H NMR chemical shift compared to the protons (HX,Y,Z) of 
(S) – MTPA ester due to the anisotropic effect of the MTPA phenyl rings (Figure 54).  
This shielding effect of the phenyl group has assumed to alter the chemical shifts of 
proton from the ring.86,89   With the modified Mosher’s method, after the determination 
of the ∆δ values (∆δ = δS – δR) for the particular compound, a molecular model is 
constructed and then confirmed that all the assigned protons with positive and negative 
∆δ values are actually found on the right and left sides of the MTPA plane, respectively 
(Figure 54). 
C
MeO
CF3
O
O
C
H
HAHBHC
HZ HY HX
δ γ β
δ' γ' β' α
MTPA plane
(R) - MTPA ester
(Ph) (OMe) (S) - MTPA ester
 
Figure 53. The MTPA plane of the (R) – MTPA and (S) – MTPA esters of a secondary 
alcohol. 
 
(R) - MTPA ester
CF3
PhMeO
O
HA
ββ'
(S) - MTPA ester
CF3
OMePh
O
HA
ββ'
HZ(β') in (R)-MTPA ester   >δ δ HZ (β') in (S) - MTPA ester
HA(β) in (R)-MTPA ester   <δ δ HA (β) in (S) - MTPA ester
HX HX
 
 
Figure 54.  Configurational correlation model for (R) and (S) – MTPA esters. 
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        The absolute values of the ∆δ = δS – δR for each proton should be proportional to 
the distance from the MTPA moiety due to the diamagnetic effect of the benzene ring of 
the MTPA to the particular proton (Figure 55).  When these conditions are satisfied, the 
MTPA model indicates the correct absolute stereochemistry. 
OMTPA
H
HC
HB
HA
HZ
HY
HX
−δ +δ
 
Figure 55.  MTPA ester model to determine the absolute configurations of secondary 
alcohols (∆δ = δS – δR) by the modified Mosher’s method assignment. 
 
       After construction of a simple molecular model, the ceramide analog (39) was 
subjected to esterification with (R) – MTPA-Cl and (S) – MTPA-Cl in the presence of 
pyridine (Scheme 6). 
NH
O
6
2'3'
2
3
4
5
HO
1
NH
O
6
2'3'
2
3 4 5
RO
1
(S) - or (R) - MTPA-Cl
pyridine, rt
overnight
R = (S) - MTPA (43)
R = (R) - MTPA (44)
OH OR
 
Scheme 6. MTPA reactions with ceramide analog (39). 
 
 
     The MTPA esters were chromatographed by normal phase silica gel with 
EtOAc/hexane (5:95).  The absolute stereochemistry of ceramide analog (39) was 
confirmed using 1H NMR spectra (Figure 56 and 57) and gCOSY analysis (Table 9 and 
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10).   All proton signals for both (S) – MTPA ester (43) and (R) – MTPA ester (44) 
were assigned and 1H NMR chemical shift differences (∆δ = δS – δR) (Figure 58) were 
determined for neighboring protons. 
8 7 6 5 4 3 2 1 PPM 
Figure 56. 1H NMR spectrum of (S) – MTPA ester (43) (500 MHz, CDCl3). 
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Figure 57. 1H NMR spectrum of (R) – MTPA ester (44) (500 MHz, CDCl3). 
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1      4.39 (1H, dd, J = 5.2, 11.6 Hz)            H2               
        4.34 (1H, dd, J = 4.0, 11.8 Hz)
2      4.55 (1H, m)                                         H1, H3, NH
3      5.39 (1H, t, J = 7.8 Hz)                        H2, H4
4      5.29 (1H, m)                                         H2, H3, H5                         
5      5.81 (1H, dt, J = 7.9, 13.4 Hz)             H4, H6
6      2.01 (2H, m)                                         H4, H5                       
2'     1.99 (2H, t, J = 8.0 Hz)                        H3'               
3'     1.49 (2H, m)                                         H2'
NH  5.27 (1H, d)                                          H2
1H(δ) gCOSY
Table 9. NMR data of (S)-MTPA ester (43) (CDCl3) 
(13C, 125 MHz; 1H NMR 500 MHz)
 
 
 
1       4.27 (1H, dd, J = 3.6, 11.5 Hz)          H2               
         4.20 (1H, dd, J = 5.5, 11.3 Hz) 
2       4.49 (1H, m)                                       H1, H3, NH   
3       5.42 (1H, t, J = 8.5 Hz)                      H2, H4    
4       5.39 (1H, m)                                       H2, H3, H5                    
5       5.90 (1H, dt, J = 5.5, 14.6 Hz)           H4, H6 
6       2.02 (2H, m)                                       H4 ,H5                
2'      2.02 (2H, m)                                       H3'               
3'      1.51 (2H, m)                                       H2'
NH   5.23 (1H, d)                                        H2
1H(δ) gCOSY
Table 10. NMR data of (R)-MTPA ester (44) (CDCl3)
(13C, 125 MHz; 1H NMR 500 MHz)
 
HN
OR
O
6
2' 3'
2345 1 OR
+ 0.06
-0.03
+ 0.12,
+ 0.14
- 0.10
- 0.09
- 0.01
+ 0.03
H -0.03
- 0.02
δ δ− +
R = (S)-MTPA (43)
R = (R)-MTPA (44)
 
Figure 58. ∆δ values (δS – δR) of the MTPA esters 43 and 44 in CDCl3. 
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       An MTPA molecular model was constructed with the - ∆δ protons on the right and 
+ ∆δ protons on the left side of the MTPA plane (Figure 59). After checking that the ∆δ 
values were qualitatively proportional to the distance from the MTPA moiety, the 
substituents about the chiral centre indicated priority by the Cahn-Ingold-Prelog rules.90  
The results, shown in Figure 59, established that the absolute stereochemistry of C-3 
was 3S configuration.  
δ δ- +
OMTPA
H
4 23
OMTPA
H
S
1
2 3
4
δ-δ+
 
 
Figure 59. Model to determine the absolute configuration of the cearamide analog (39) 
MTPA esters. 
 
 
The relative stereochemistry of C-2 was determined with Chem3D software 
from Cambridge Soft Corporation. The carbon-2 was assumed to have R configuration 
and carbon-3 to have S configuration. The dihedral angles (Figure 60) of H-2 (C-2), H-3 
(C-3), and H-4 (C-4) were obtained from Chem3D with minimized energy condition by 
computational calculations.   The possible proton-proton dihedral angles showed 173˚ 
between H-3 and H-2, 163˚ between H-3 and H-4.  The relative dihedral angles 
suggested that H-3 was located in anti configuration between H-4 and H-2 and the 
possible coupling constant (1,3JHH) should be triplet multiplicity.   The relative dihedral 
angles showed 91˚ indicating gauch form between H-2 and H-1a, 147˚ indicating anti 
form between H-2 and H-1b suggesting that H-2 is multiplet.  
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Figure 60. Dihedral angles of H-3, H-4 proposed with 3 (S) and 2 (R) of ceramide 
analog (39).   
 
When the carbon-2 was assumed to have S configuration, the possible proton-
proton dihedral angles  (Figure 61) calculated by Chem3D showed 63˚ between H-3 and 
H-2, 166˚ between H-3 and H-4.  
HN
OH
O
6
2' 3'
2345 1 OHS S
CH3
HO H
CH2OH
HHN
63 o
CH2
166 o
H
3
2
4
3H
HC OH
OH
H H
NH
CHH
1b1a
2
63 o
173 o  
Figure 61. Dihedral angles of H-3, H-4 proposed with 3 (S) and 2 (S) in ceramide 
analog (39).  
 
The dihedral angle showing 63˚ suggested a gauche arrangement between H2 
and H3 and the dihedral angle showing 166˚ suggested an anti arrangement between H3 
and H4.  Therefore, H3 when assumed as 3S and 2S configurations has to display two 
different multiplicities which are doublet and doublet, however the actual multiplicity of 
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C-3 in ceramide analog (9) is triplet (1,3JHH = 4.9 Hz) between H-3 and H-6.  The 
relative dihedral angles also showed 63˚ indicating gauch form between H-2 and H-1a, 
173˚ anti form between H-2 and H-1b suggesting that H-2 is multiplet.  Thus C-3 (S) 
and C-2 (R) are favorable configurations than C-3 (S) and C-2 (S) in ceramide analog 
(9) by Chem3D.  The relative configuration (Figure 62) of C-6 is suggested to be R and 
C-3 (S) indicates triplet multiplicity of H-3. 
HN
OH
O
OHR
S
 
Figure 62. Relative stereochemistry of ceramide analog (39). 
 
The Chem 3D models with C-3 in S configurations and C-2 in R configuration 
showed almost the same dihedral angle between H-2 and H-4 which are 173˚ and 163˚. 
This indicates that H-3 is not a double-doublet, but a triplet.   However, theoretically the 
coupling constant (1,3JHH) of H-3 between two protons, H-2 and H-4 with dihedral 
angles, 163˚ and 173˚ should be above 1,3JHH = 5 Hz.  The Mosher’s method and the 
Chem3D models are showing that C-3 is in the S configuration and C-2 is in R-
configuration.  Also, the acetylated aminodiol 42 showed that H-4 is a triplet with 
coupling constant with 1,3JHH = 6.6 Hz.  The dihedral angle between H-2 and H-3 in this 
product is also the same as that in ceramide analog (39).  Except for the coupling 
constants in ceramide, all the other models are showing as C-3 (S) and C-2 (R) rather 
than C-3 (S) and C-2 (S).  Hence, the relative configuration of C-2 is suggested to be R 
configuration from the results of Chem3D and C-3 (S) indicates triplet multiplicity of 
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H-3 from the Mosher’s method.  From the mass spectrometric data of ceramide analog 
(39), methanolysis reaction, and Mosher’s method, the chemical structure of ceramide 
analog (39) was suggested in Figure 63 with Table 11.   
HN
OH
OH
O
1'
2'
24'
23'
20
1234510
6
17
18
19
 
Figure 63. Ceramide analog (39). 
 
 
1        3.97 (1H, dd, 3.8, 11.0)    62.4 (CH2)     H2               H2, H3, NH          C2, C3
          3.71 (1H, dd, 3.3, 11.3)                           H2               H2, H3, NH
2        3.91 (1H, m)                     54.9 (CH)       H3, NH       H1, H4, H5          C4, C1'
3        4.34 (1H, t, 5.0)                74.2 (CH)       H2, H4        H1, H2, H4,         C1, C2, C4, 
                                                                                               H5, H6, NH         C5
4        5.54 (1H, dd, 6.6, 15.6)   129.1 (CH)      H3, H5        H3, H5, H6           C2, C3, C6
                                                                                               H7, NH
5        5.80 (1H, dt, 7.4, 15.5)    134.2 (CH)      H4, H6        H3, H4, H6, H7    C3, C6
6        2.02 (2H, m)                      32.6 (CH2)    H5, H7         H3, H4, H5, H7    C4, C5, CH2
7        1.40 (2H, m)                      27.9 (CH2)    H6, H8         H3, H4, H5, H6    C6, CH2       
8-15   1.28 (16H, m)
16       1.17 (2H, m)                      39.8 (CH2)    H17             H17, H18,            C17, C18,  
                                                                                               H19                      C19, CH2   
17       1.54 (1H, heptet, 6.7)        28.2 (CH)      H16, H18    H16, H18, H19    C16, C18, 
                                                                            H19                                          C19            
18       0.88 (3H, d, 6.8)               22.9 (CH3)     H16, H17    H16, H17             C16, C17
19       0.88 (3H, d, 6.8)               22.8 (CH3)     H16, H17    H16, H17             C16, C17
1'                                                174.5 (C) 
2'        2.24 (2H, t, 7.5)                37.0 (CH2)      H3'              H3', CH2              C1', C3', CH2
3'        1.60 (2H, m)                     26.0 (CH2)      H2'              H2', CH2              C1', C2', CH2
4'- 23' 1.28 (34H, m)                                             
24'      0.90 (3H, t, 7.0)                14.3 (CH3)      H23'            H23', CH2 
NH     6.24 (1H, d, 7.7)                                       H2               H1, H2, H3, H4   C1, C2, C3, 
                                                                                                H5, H6                 C1'
1H (δ, J, Ηz) 13C (δ) gCOSY gHMBCTOCSY
Table 11. NMR data of ceramide analog (39)  (CDCl3) (13C, 125 MHz; 1H, 500 MHz)
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Chapter 5. TOTAL SYNTHESIS OF THE NATURAL PRODUCT 
EREBUSINONE AND EREBUSINONAMINE 
 
5.1 Introduction. 
 
The Antarctic benthos is characterized by a dominant sponge community. 
Sponge predators include sea stars, nudibranchs and amphipods, though some sponge 
species appear to lack predation.   Our own chemical ecological investigations of 
Antarctic invertebrates led to us to investigate the sponge Isodictya erinacea (Topsent, 
1916) (Family Esperiopsidae), collected in McMurdo Sound, Antarctica, because I. 
erinacea appeared to be free of predation despite its lack of structural protection 
elements such as spicules.59   I. erinacea was found to elaborate a host of secondary 
metabolites bearing cytotoxicity and ecological activities.60, 61 We have documented 
molt-inhibition activity of sponge extracts toward the sympatric amphipod Orchomene 
plebs, a common predator of McMurdo Sound sponges.    In laboratory assays carried 
out at McMurdo Station, amphipods were fed diets composed of either nutritionally 
rich control agar pellets or the same pellets to which an ecologically relevant (i.e., on a 
volume/volume basis relative to that found in the sponge) sponge extract had been 
added; the sponge extracts were substantially enriched with erebusinone (12), a yellow 
pigment we had previously isolated from the sponge. 61 
  
We monitored food consumption, molt events and mortality.   Feeding was 
vigorous in both groups of amphipods as control and experimental (erebusinone-
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enriched) diets.  Over the 4 week experiment, the consumption and mortality of 
amphipods (Figure 64) were significantly higher in erebusinone-enriched diet and molt 
events significantly reduced; leading us to suggest that erebusinone interferes with 
molting in O. Plebs leading to premature mortality (Figure 65). 
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Figure 64. Occurrence of mortality in O. plebs fed erebusinone in their diet. 
 
 
 
 
 
 
 
Figure 65. Occurrence of molting in O. plebs fed erebusinone in their diet. 
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3-Hydroxykynurenic acid
OH
NH2
O
Erebusinone
OH
NH2
O
NHAc
NH2
O
OH
(12) (24)  
          Molt inhibition as a chemical defense mechanism has not previously been 
documented in marine systems.  We believe that erebusinone (12) is acting as a 3-
hydroxykynurenine (24) mimic.  3-Hydroxykynurenine is a tryptophan catabolite 
intermediate in the biosynthesis of xanthurenic acid, a quinoline alkaloid inhibitor of 
the cytochrome P450 oxidase responsible for oxidizing ecdysone (Figure 66) to 20-
hydroxyecdysone, the latter of which is the molt regulator of crustaceans (Figure 67, 
68).74,91    To further investigate the bioactivity and ecological role of erebusinone, we 
have carried out the synthesis of the yellow pigment, erebusinone.   
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Figure 66.  Ecdysone metabolism. 
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Figure 67. Tryptophan Catabolism. 
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Figure 68. Overlay of erebusinone (12) with 3-hydroxykynurenine (24) 
in a hypothetical receptor. 
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5.2 Synthesis of Erebusinone (12) 
 
       The yellow pigment from the Antarctic sponge Isodictya erinacea, erebusinone has 
been implicated in molt inhibition and mortality against Antarctic crustacean amphipods, 
perhaps serving as a precursor of a xanthurenic acid analog.   Our interest in 
erebusinone bioactivity led us to develop the synthesis, which we have achieved in an 
overall yield of 44% involving seven steps.    The synthetic pathway also features an 
economical and efficient preparation of erebusinone. 
 
5.3 Results and Discussion 
 
       We developed a convenient and efficient total synthetic strategy of erebusinone 
(12).    As shown in Scheme 7, we initially pursued the synthesis of the 3-benzyloxy-2-
nitrobenzylbenzoate (46) using 3-hydroxy-2-nitro benzoic acid (45) as a starting 
material. Benzyl bromide treatment with solid K2CO392 in dry DMSO at ambient 
temperature gave the dibenzyl ester (46) in 95% yield.  
 
       To elaborate the side chain, we envisioned that the extension of aliphatic carbon 
chains could be achieved by lithium acetonitrile generated in situ by the treatment of 
acetonitrile and n-butyllithium.93  The treatment of lithium acetonitrile with dibenzyl 
ester 46 through direct SN2 substitution provided a 90% yield of the resulting ketontrile 
47. To prepare amino alcohol 49, we had to establish the reduction conditions for the 
conversion of the nitrile to amine.  At this stage, our initial attempts of sequential 
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reduction of ketone and nitrile proved to be more difficult than we had expected.  
Numerous attempts to perform reduction of 47 and 48 with LiAlH4, NaBH4 with 
CoCl2,94,95 and hydrogenation failed.96   However we finally achieved a successful 
reduction to afford amino alcohol 49 in a two step procedure by NaBH4 and 
dimethylsulfide borane (BH3SMe2).97   The reduction of compound 48 with 2.0 equiv 
of aqueous sodium borohydride (NaBH4) afforded the corresponding intermediate 48 
in 95 % yield, which was further treated with 2.4 equiv of BH3SMe2 in refluxing dry 
THF, providing the desired hydroxyl amine 49 in 76% overall yield via two-step 
reduction sequence involving ketone reduction of 47 and nitrile reduction of 48.   
OBn
NO2
O
OBn
OH
NO2
O
OH K2CO3/BnBr
DMSO
95%
OBn
NO2
O
CN
BuLi/CH3CN
THF/- 78 oC
90%
NaBH4/H2O
MeOH
95 %
OBn
NO2
OH
CN
THF
83%
BH3S(CH3)2
OBn
NO2
OH
NH2
(45) (46)
(47)
(48) (49)  
 
Scheme 7. Synthetic route to erebusinone precursor 49 
 
       The selective protection reaction (Scheme 8) of the intermediate 49 was carried 
out by the selective protection of the primary amine98 with 1.2 equiv of acetic 
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anhydride in the presence of triethylamine in dry dichloromethane at ambient 
temperature providing 82% yield of the protected acetylamide 50.  Oxidation of 
secondary alcohol 50 by Dess-Martin oxidation99 led to the formation of the desired 
the ketone 51 in 90 % yield. 
OBn
NO2
OH
NHAc
OBn
NO2
OH
NH2
Ac2O
triethylamine
CH2Cl2
82%
OBn
NO2
O
NHAc
Dess Martin
oxidation
CH2Cl2
90%
Erebusinone (12)
H2, Pd/C, 1 atm
EtOH
93% OH
NH2
O
NHAc
(49) (50)
(51)
 
Scheme 8. Synthetic route from erebusinone precursor 49 to erebusinone (12). 
 
       To complete the synthesis of erebusinone 12, we needed to remove the protected 
benzyl group and reduce the nitro group.  For the purpose of this study, we considered 
that the intermediate 51 had to be converted into erebusinone 12 in a one-pot reaction.    
Exposure of 51 in absolute ethanol to Pd/C (10%)96 at ambient temperature under a 
hydrogen atmosphere (1 atm) worked well with mild conditions leading to erebusinone 
12 in 93% yield (Scheme 8). 
 
       In summary, we have developed a highly convenient synthetic pathway of 
erebusinone (12) providing an overall 44% yield.  To further evaluate the biological 
activities of erebusinone (12) and its analogs, the explored synthetic method should 
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hold promise for the preparation of various structural types of erebusinone congeners 
with potential molt inhibition activity.  We have envisioned analogs of erebusinone 
with different substitution patterns on the aromatic ring, with differing side chain 
lengths, and with additional oxidation levels. 
  
5.4 Synthesis of Erebusinonamine (52) 
 
       The utility of our synthesis of erebusinone (12), besides being brief and high-
yielding, is the opportunity to afford its analogue synthesis.  Our ongoing research 
focuses on the preparation of analogues and the evaluation of the potential role of these 
compounds as molt inhibitors.  Analogues with different substitution patterns on the 
aromatic ring, with differing side chain lengths, and with additional oxidation levels are 
envisioned.  The synthesis of erebusinononamine (52), the deacetylated terminal amine 
was the first erebusinone analog synthesis attempted.  
 
OH
NH2
O
NHAc
OH
NH2
O
NH3Cl
Erebusinone (12) Erebusinonamine (52)  
 
5.5 Results and Discussion 
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       In our previous study, the synthesis of erebusinone (12) was achieved and the 
synthesis of erebusinonamine (52) was pursued from an intermediate of erebusinone, 
hydroxylamine (49).  Erebusinonamine (52) was synthesized following the reaction 
sequence depicted in Scheme 8. Hydroxylamine 49 was reacted with di-tert-butyl 
dicarbonate (Boc2O)100 to afford the tert-BOC carbamate 53 in 100% yield and then 
followed by Dess-Martin oxidation to give compound 54 in 80% yield.  The 
deprotection of t-BOC group101 was achieved in the presence 55 with HCl (1.25 M) to 
afford precursor of erebusinonamine in 100% yield.  Finally, erebusinonamine (52) 
was prepared by reaction of 55 with Pd/C96 under 3.5 atm in 90% yield. 
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Scheme 9. Synthetic route of erebusinonamine (52) from erebusinone precursor 49. 
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Chapter 6. BIOASSAY OF PURE COMPOUNDS 
 
Bioassays for the pure compounds were done at Wyeth Pharmaceuticals and 
also at Marine Natural Products Lab at University of South Florida.  Antimicrobial 
activities were carried out with the isolated compounds purine analog (23), ceramide 
analog (39), synthetic compounds, erebusinone (12) and erebusinonamine (52) using 
standard disk diffusion method against two gram-positive bacteria, Staphylococcus 
aureus (Sa, strain 375) and Staphylococcus meth resistant (Sa, strain 310), against one 
gram-negative bacteria Escherichia  faecium van resistant (Ef, strain 379), and against a 
fungus Candida albicans (Ca, strain 54).102  Assay plates were prepared by pouring 125 
mL volume of agar medium (tempered at 50°C) inoculated with an overnight broth 
culture of the test organisms.  Sample concentrations of 100 µg in 10 µL aliquots were 
spotted onto agar surface and the plates were incubated at 37°C for 24-48 h.  The zones 
of growth inhibition were measured from the edge of the disk to the edge of the clear 
inhibition zone in mm, respectively.  Control disks were treated with solvent alone 
(MeOH or CHCl3). 
Synthetic erebusinone (12)
Erebusinonamine (52)
Sa375 Sa310 Ef379 Ca54
0 0 0 0
8 8 6 10
Sa375: Staphylococcus aureus, Sa310: Staphylococcus meth resistant,
 Ef379: Escherichia  faecium van resistant, Ca54: Candida albicans
Ceramide analog (39) 7 7 6 9
Purine analog (23) 0 0 0 0
Table 12 . Antimicrobial activity of pure compounds (100 µg/disk) 
                  using the disk diffusion assay (Zone of Inhibition in mm)
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The purine analog (23) did not show considerable antimicrobial activity.  
Ceramide analog (39) showed modest antimicrobial activity against Staphylococcus 
aureus (Sa, strain 375), Staphylococcus meth resistant (Sa, strain 310), Escherichia  
faecium van resistant (Ef, strain 379) and Candida albicans (Ca, strain 54).  
Erebusinonamine (52) showed relatively better activity against Candida albicans (Ca, 
strain 54) than Staphylococcus aureus (Sa, strain 375), Staphylococcus meth resistant 
(Sa, strain 310) and Escherichia  faecium van resistant (Ef, strain 379).  Erebusinone 
(12) did not show considerable antimicrobial activity. Erebusinone (12) is presently 
being tested for insecticidal activity. 
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Chapter 7. DISCUSSION 
 
        Isodictya erinacea has been found to produce unusual molt inhibitor precursor 
analog erebusinone (12), purine derivatives (13, 21, 22, 23) and nucleosides 
metabolites and exhibits an unusual chemical defense role against a major sponge 
predator, the sea star Perkanster fuscus, as well as the amphipod Orchomene plebs.60,61  
Our chemical and ecological investigations of the Antarctic invertebrates led us study 
the marine sponges, Isodictya erinacea, Isodictya setifera and Isodictya antarctica.   
 
        Isodictya erinacea was found to produce an unusual N-methylated purine analog 
23 and 3-hydroxykynurenine (24), the precursor of molting inhibitor xanthurenic acid.  
N-methylated purine base analogues previously reported including from various 
sponges, 1,9-dimethyl-6-imino-8-oxopurine from Hymeniacidon sanguinea,103,104  
1,3,7-trimethylguanine from Latrunculia brevis,71 herbipoline (7,9-dimethylguanidium 
salt) and 1-methyl adenine from Geodia gigas, 105 longamide (3,7-dimethylisoguanine) 
from Agelas lingissima,106 1,3-dimethylisoguanine from Amphimedon viridis,107 
mucronatine (2-methoxy-3-methylisoguanine) from Styphnus mucronatus.108  The 
purine 1,3,7-trimethylisoguanine was also isolated from the Ascidian Pseudodistoma 
cereum.72  
 
Chemical investigation of Isodictya setifera led to the isolation of known 
secondary metabolites, homarine (37), 5-methyl-2-deoxycytidine (25), uridine (28), 
2’-deoxycytidine (31), 4, 8-dihydroxyquinoline (33), 3-hydroxykynurenine (24), of 
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which the latter two are known biosynthetic intermediates of tryptophan catabolism in 
crustaceans.  The first discovery of purine and nucleosides were isolated from the 
marine sponge Cryptothethya crypta by Bergmann and co-workers in the 
1950’s.41,42,109,110  The modified unusual halogenated nucleosides also isolated from 
sponges and algae.111-115  Therefore, marine sponges are well known as source of 
nucleosides and purine derivatives.  
 
Among the potential ecological roles of the sponges ion the Antarctic benthos, 
previously we reported that the secondary metabolite, erebusinone (12) from Isodictya 
erinacea has been implicated in molt inhibition and mortality against an Antarctic 
crustacean, Orchomene plebs, perhaps serving as a precursor of xanthurenic acid analog. 
We documented significant molt inhibition activity against common sponge predator 
crustacean amphipods.60,61  The secondary metabolites, 4,8-dihydroxyquinoline (33), 3-
hydroxykynurenine (24), from the Antarctic sponge I. setifera, are known to participate 
in the regulatory pathway of crustacean molting via tryptophan catabolism.60,61  This 
appears to be the first example in marine realm that sponges produce tryptophan 
catabolism intermediates to that interfere molting in O. plebs for chemical defense.  
According to our previous metabolite profile, biological activities and ecological 
implications, we believe species of the genus Isodictya is distinctive in producing 
biosynthetically unique and various secondary metabolites and suggest that I. setifera 
and I. erinacea may play a role in chemical defense.  
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Chemical investigation of I. antarctica was found to produce ceramide analog 
which showed antimicrobial activity against Staphylococcus aureus, Staphylococcus 
meth resistant, Escherichia faecium van resistant and Candida albicans. A variety of 
ceramide derivatives have been reported from marine sponges.116-118 Relative 
stereochemistry of ceramide analog (39) was assigned by Mosher’s method and 
Chem3D.86   
 
        We have developed mild, simple, and efficient synthetic methods for erebusinone 
(12) and erebusinonamine (52) in excellent yields from 3-hydroxy-2-nitro benzoic acid 
(45) and we also optimized each synthetic conditions of erebusinone (12) and 
erebusinonamine (52) from 1 to 20 gram.   The bioassays of synthetic natural product, 
erebusinone (12) did not show antimicrobial activity but, erebusinonamine (52) 
showed moderate antimicrobial activity against Staphylococcus aureus, Staphylococcus 
meth resistant, Escherichia  faecium van resistant and Candida albicans.  The 
ecological and biological assays of these compounds as molt inhibitors are currently 
under investigation. 
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Chapter 8. EXPERIMENTAL 
 
8.1 General Procedure.  
 
       Flash column chromatography was performed on EM Science normal phase Silica 
gel 60 (200 – 400 mesh).  Thin layer chromatography (tlc) was carried out using 
Whatman normal phase Silica gel 60Å  Partisil® K6F, reversed phase Silica gel 60Å 
Partisil® KC18F, and CNF254s plates 0.25 mm thickness.  There were visualized by 
spraying with 5% phosphomolybdic acid in EtOH and heating and 2 % ninhydrin in 
BuOH/acetic acid (95:5). HPLC (high performance liquid chromatography) was 
performed on Waters 510 equipped with a Waters 490E programmable multiwavelength 
UV detector at 254 nm and Shimadzu LC-8A equipped with a multisolvent delivery 
system connected to a Shimadzu SPD-10A UV-VIS tunable absorbance detector and/or 
an Alltech ELSD 2000 using a YMC-Pack® ODS-AQ C-18 analytical column, a Waters 
prepLC®
 
(25 mm X 30 cm) C-18 column for reversed phase, or Waters 
Sphereclone®(250 X 10 mm) for normal phase.  Infrared (IR) spectra were obtained 
with Nicolet Avatar 320FT-IR in solid state.  Ultraviolet-Visible (UV) experiments 
were measured on a Hewlett-Packard 8452A diode array UV/Vis spectrometer.  High 
resolution mass spectra ESI-MS (negative or positive mode), EI-MS (negative or 
positive mode) and CI-MS were obtained on Micromass 70-VSE spectrometer at the 
University of Illinois.  Optical rotation was determined on a Rudolph Research 
Analytical AUTOPOL® IV with a sodium lamp (589 nm) and 0.5 dm cell.   1H NMR 
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and 13C NMR spectra were recorded at 250 MHz and 75 MHz, respectively on a Bruker 
AMX-250 or 500 MHz and 125 MHz, respectively on a Varian INOVA-500.    1H and 
13C NMR chemical shifts are listed relative to CDCl3 (δ 7.27), MeOH-d4 (δ 3.31), or 
DMSO-d6 (δ 2.50) and (δ 77.00), (δ 49.00), or (δ 39.50) respectively.  The 13C 
resonance multiplicities were determined by DEPT experiments.  1H-1H correlations 
were determined by using gCOSY and TOCSY experiments optimized coupling 
constant (JHH of 7 Hz).   One bond connectivities (1JCH) of 1H-13C were determined via 
the 2-D proton-detected gHSQC experiment.  The interpulse delays were optimized for 
average 1JCH of 120 MHz. Two- or three-bond heteronuclear multiple-bonds (3JCH/2JCH) 
were recorded via the 2D proton detected gHMBC experiment optimized for a long 
range coupling constant (JCH of 7 Hz).   Unless otherwise specified, materials were 
purchased from commercial suppliers and used without further purification. Low-
temperature baths of –78 ˚C and – 40 ˚C were obtained with an immersion cooler bath 
using acetone and CH3CN with dry ice (CO2).  THF was distilled from sodium and 
benzophenone immediately before use.  CH2Cl2 and CH3CN were distilled from CaH2 
under argon and triethylamine from KOH. Moisture-sensitive reactions were conducted 
in oven or flame-dried glassware under and argon atmosphere.  Unless otherwise noted, 
all organic layers were dried with over either anhydrous Na2SO4 or MgSO4 and 
concentration of all solutions was accomplished by a rotary evaporator at water 
aspirator pressures. Melting points were uncorrected. 
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8.2 Isolation of Secondary Metabolites from Isodictya erinacea 
 
       A specimen of  Isodictya erinacea was collected by using SCUBA diving (-20 - 30 
m) at Erebus Bay on the western coast of Ross Island, Antarctica in summer 1999. The 
freshly collected marine sponge was frozen in liquid nitrogen immediately to prevent 
degradation of the pigment.  A voucher specimen has been deposited in a – 70 ˚C 
freezer at the Department of Chemistry, University of South Florida.  The body of I. 
erinacea is yellow or light brown both inside and outside, and the surface is globular 
and spiny. 
 
       The marine sponge (1.0 kg, wet) which was kept frozen until use was exhaustively 
extracted with MeOH (2L X 5 times) at 7 ˚C.  After concentration, the extract was re-
dissolved with MeOH to remove salt.  The residual fraction (20g) was subjected to 
Sephadex LH-20® column chromatography (5 cm X 60 cm) with CH2Cl2/MeOH (1:1) 
to provide 5 fractions. Fraction 4 (1.1g) was further subjected to C18 column 
chromatography (2.5 X 45 cm) with a MeOH/CH2Cl2 (100:0 → 0:100) gradient system 
to give four fractions.  Fraction 8 (374 mg) was chromatographed on silica gel column 
(2.5 cm X 45 cm) with H2O/MeOH/CHCl3 (0.4:3.0:6.6) to provide 4 fractions.  Purine 
analog (23) (0.0068 %, 68 mg) was obtained from fraction 11 (104 mg) on silica gel 
column (2.5 cm X 30 cm) with H2O/MeOH/CH2Cl2 (0.4:30:66).  Fraction 12 was 
chromatographed on silica gel (2.5 cm X 30 cm) eluting with H2O/MeOH/CH2Cl2 
(0.5:4:5.5) to yield 3-hydroxykynurene (24), fraction 20 (0.00135%, 13.5 mg) (Scheme 
1). 
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8.2.1 Spectral data of Purine analog (23) 
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1,3,7-Trimethylisoguanine: a pale brown crystal; mp decomposed at 230 ˚C ; IR vmax 
3303, 3241, 3089,1715, 1641, 1567, 1026 cm-1; UV (MeOH) λmax (log ε) 210 (2.02), 
268 (0.75) nm; 1H NMR (DMSO-d6, 500 MHz): δ 8.17 (s, 1H, H-8), 3.88 (s, 3H, N-7-
CH3), 3.61 (s, 3H, N-3-CH3), 3.36 (s, 3H, N-1-CH3); 13C NMR (DMSO-d6, 125 MHz)  
152.5 (s, C-6), 151.3 (s, C-2), 147.6 (s, C-4), 143.6 (d, C-8), 106.9 (s, C-5), 33.4 (q, N-
7-CH3), 32.2 (q, N-3-CH3), 29.3 (q, N-1-CH3); HREIMS m/z 193.0959 (calcd for 
C8H11N5O1, 193.0964), LREIMS m/z [M+] 193.1 (100 %), [M-NH]+ 178.1, [M-CHO]+ 
164.1 (20 %), [M-HNCNCH3]+ 138.1 (12 %), [M-CO]+ 109.0 (30 %), [M-HCN]+ 82.1 
(24 %). 
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8.2.2 Spectral data of 3-Hydroxykynurenine (24) 
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3-Hydroxykynurenic acid; bright yellow solid; [α]25D -47.6˚ (c = 0.17, MeOH); IR vmax 
3339, 2981,1685, 1611, 1533, 1275 cm-1; UV (MeOH) λmax (log ε) 234 (1.06), 273 
(0.36), 381 (0.21) nm; 1H NMR (DMSO-d6, 500 MHz) δ 7.19 (1H, d, J = 8.2 Hz, H-1), 
6.85 (1H, d, J = 7.6 Hz, H-2), 6.40 (1H, t, J = 8.0 Hz, H-4), 3.62 (1H, d, J = 7.8 Hz, H-
5), 3.50 (1H, dd, J = 2.3, 18.1 Hz, H-6), 3.24 (1H, dd, J =  8.6, 17.5 Hz); 13C NMR 
(DMSO-d6, 125 MHz) δ 200.0 (s, C-12), 170.3 (s, C-11), 145.5 (s, C-10), 141.6 (s, C-9), 
121.6 (d, C-1), 117.4 (d, C-2), 117.1 (s, C-8), 114.6 (d, C-4), 50.5 (d, C-5), 41.1 (t, C-6). 
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8.3 Isolation of Secondary Metabolites from Isodictya setifera 
 
The marine sponge Isodictya setifera was collected by using SCUBA from 
Bahia Paraiso on the coast near Palmer station, Antartica at depths of 40-50 m on 28 Jan 
2003.  The marine sponge, Isodictya setifera (435g, freeze dried) was first extracted 
with methanol (3L X 3 times) at room temperature.  After concentration, the crude 
extract was partitioned with hexane/MeOH/H2O (400 mL/500 mL/100 mL).  The 
hexane layer was separated and concentrated to give a crude extract (9.0 g) and aqueous 
layer was partitioned with CH2Cl2/MeOH/H2O (400 mL/500 mL/100 mL) and the 
organic layer was separated and concentrated to give CH2Cl2/MeOH extract (8.3 g).  
The aqueous layer was extracted with BuOH which gave a BuOH extract (1.9 g) and the 
aqueous extract was concentrated to provide the H2O extract (38g).  BuOH extract 
(1.9g) was subjected to Sephadex LH-20® column (5 cm X 60 cm) with MeOH to 
provide seven fractions.  Fraction 12 (570 mg) was further subjected to normal phase 
silica gel column (2.5 X 45 cm) with a MeOH/CH2Cl2 (0:100 → 30:70) and 
CH3CN/H2O (100:0 → 80:20) and followed by HPLC with reversed cyano column  
using AcCN/H2O (99:1 → 80:20) to give pure compounds which are 3-
hydroxykynurenine (24) (1.7 mg, 0.0004% yield), 5-methyl-2’-deoxycytidine (25) (3 
mg, 0.0007% yield), uridine (28) (2.0 mg, 0.0005% yield), 2’-deoxycytidine (31) (1.5 
mg, 0.0003% yield), 4,8-dihydroxyquinoline (33) (1.8 mg, 0.0004% yield), homarine 
(37) (2.0 mg, 0.0005% yield) (Scheme 3).  
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8.3.1. Spectral data of 5-Methyl-2’-deoxycytidine (25) 
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5-Methyl-2’deoxycytidine; white solid: [α]25D +5.3˚ (c = 0.15, MeOH); IR vmax 2918, 
1688, 1469, 1236, 1090 cm-1; UV (MeOH) λmax (log ε) 209 (0.88), 268 (0.83) nm; 1H 
NMR (MeOH-d4, 500 MHz) δ 7.83 (1H, s, H-1), 6.30 (1H, t, J = 6.8 Hz, H-2’), 4.42 
(1H, m, H-4’), 3.92 (1H, q, J = 3.4, H-5’), 3.81 (1H, dd, J = 3.2, 12.5 Hz, Ha-6’), 3.74 
(1H, dd, J = 3.5, 11.8 Hz, Hb-6’), 2.25 (2H, m, H-3’), 1.89 (3H, s, H-7); 13C NMR 
(MeOH-d4, 125 MHz) δ 165.3 (s, C-5), 151.2 (s, C-3), 136.7 (d, C-1), 110.4 (s, C-6), 
87.6 (d, C-5’), 85.1 (d, C-2’), 71.0 (d, C-4’), 61.7 (t, C-6’), 40.0 (t, C-3’), 11.3 (q, C-7). 
 
 
 
 
 
 
 90
8.3.2. Spectral data of Uridine (28) 
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5-Methyl-2’deoxycytidine; white solid: [α]25D 0˚ (c = 0.1, MeOH); IR vmax 2984, 2902, 
1687, 1235, 1207, 1089 cm-1; UV (MeOH) λmax (log ε) 209 (1.01), 265 (0.56) nm; 1H 
NMR (DMSO-d6, 500 MHz) δ 7.88 (1H, d, J = 7.9 Hz, H-1), 5.77 (1H, d, J = 5.8 Hz, 
H-2’), 5.64 (1H, d, J = 8.3 Hz, H-6), 5.37 (1H, d, J = 5.9 Hz, H-3”), 5.10 (1H, m, H-4”), 
4.01 (1H, q, J = 5.4 Hz, H-3’), 3.95 (1H, q, J = 4.6 Hz, H-4’), 3.83 (1H, q, J = 3.3 Hz, 
H-5’), 3.61 (1H, m, Ha-6’), 3.54 (1H, m, Hb-6’); 13C NMR (DMSO-d6, 500 MHz): δ 
163.8 (s, C-5), 151.4 (s, C-3), 141.4 (d, C-1), 102.4 (d, C-6), 88.3 (d, C-2’), 85.5 (d, C-
5’), 74.2 (d, C-3’), 70.5 (d, C-4’), 61.5 (t, C-6’). 
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8.3.3. Spectral data of 2’-Deoxycytidine (31) 
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2’-Deoxycytidine; white solid: [α]25D +7.1˚ (c = 0.07, MeOH); IR vmax 2977, 2917, 1685, 
1235, 1089 cm-1; UV (MeOH) λmax (log ε) 209 (0.75), 265 (0.65) nm; 1H NMR 
(DMSO-d6, 500 MHz) δ 11.27 (2H, br s, NH2), 7.84 (1H, d, J = 8.1 Hz, H-1), 6.14 (1H, 
t, J = 6.2 Hz, H-2’), 5.63 (1H, d, J = 8.1 Hz, H-6), 5.23 (1H, br s, OH-4”), 5.00 (1H, br s, 
OH-6”), 4.27 (1H, m, H-4’), 3.77 (1H, m, H-5’), 3.55 (2H, m, H-6’), 2.08 (2H, m, H-
3’); 13C NMR (DMSO-d6, 125 MHz) δ 163.8 (s, C-5), 151.1 (s, C-3), 141.2 (d, C-1), 
102.4 (d, C-6), 88.0 (d, C-5’), 84.8 (d, C-2’), 71.1 (d, C-4’), 61.9 (t, C-6’), 40.2 (t, C-3’). 
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8.3.4. Spectral data of 4, 8-Dihydroxyquinoline (33) 
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4,8-Dihydroxyquinoline; white solid: IR vmax 2976, 1574, 1525, 1285, 1235, 1089 cm-1; 
UV (MeOH) λmax (log ε) 227 (1.2), 263 (0.3), 325 (0.4) nm; 1H NMR (DMSO-d6, 500 
MHz) δ 7.72 (1H, d, J = 7.2 Hz, H-1), 7.50 (1H, dd, J = 1.4, 7.9 Hz, H-2), 7.09 (1H, t, J 
= 7.7 Hz, H-3), 7.04 (1H, dd, J = 1.5, 7.7 Hz, H-4), 6.00 (1H, d, J = 7.3 Hz, H-5); 13C 
NMR (DMSO-d6, 125 MHz) δ 177.8 (s, C-9), 147.8 (s, C-8), 139.4 (d, C-1), 131.1 (s, 
C-7), 127.4 (s, C-6), 123.6 (d, C-3), 115.4 (d, C-2), 114.8 (d, C-4), 109.2 (d, C-5). 
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8.3.5. Spectral data of Homarine (37) 
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Homarine; white solid: IR vmax 2976, 1652, 1610, 1373, 1235, 1089 cm-1; UV (MeOH) 
λmax (log ε) 206 (0.8), 280 (0.6); 1H NMR (DMSO-d6, 500 MHz) δ 8.72 (1H, d, J = 6.0 
Hz, H-1), 8.42 (1H, t, J = 7.9 Hz, H-2), 7.90 (1H, dd, J = 1.3, 7.8 Hz, H-3), 7.85 (1H, t, 
J = 6.9 Hz, H-4), 4.28 (3H, s, N-CH3); 13C NMR (DMSO-d6, 125 MHz) δ 161.8 (s, C-7), 
156.7 (s, C-6), 145.7 (d, C-2), 145.0 (d, C-1), 126.0 (d, C-3), 125.5 (d, C-4), 46.5 (q, C-
5). 
 
 
 
 
 
 
 
 
 
 94
8.4 Isolation of Secondary Metabolite from Isodictya antarctica 
 
       The marine sponge Isodictya antarctica was collected by using SCUBA on the 
Bahia Paraiso on the coast near Palmer station, Antartica 2001.  A voucher specimen 
was freeze dried in the laboratory of marine natural products laboratory in the 
department chemistry at University of South Florida.   
 
The marine sponge, Isodictya antarctica (141g, freeze dried) was first extracted 
with methanol (1L X 3 times) at room temperature.  After concentration, the crude 
extract (10g) was partitioned with CH2Cl2/MeOH/H2O (500 mL/100 mL/ 100 mL).  The 
organic layer was separated and concentrated to give CH2Cl2 extract (5.7 g).  An 
aqueous layer was partitioned with BuOH/H2O (400 mL/100 mL). The BuOH layer was 
separated and concentrated to give BuOH extract (1.7 g).  An aqueous layer was 
concentrated to provide H2O extract (1.8 g). The CH2Cl2 extract (5.7 g) was subjected 
to normal phase silica gel (2.5 X 45 cm) with EtOAc/hexane (25:75 → 100:0) and 
EtOAc/MeOH (90:10 → 70:30) to give six fractions.  Fraction 4 and fraction 5 (556 
mg) was combined and subjected over Sephadex LH-20® column (5 cm X 60 cm) with 
MeOH/CH2Cl2 (1:1) followed by silica gel with EtOAc/hexane (20:80 → 100:0) to give 
ceramide analog (39) (104 mg, 0.07% yield) (Scheme 4). 
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8.4.1 Spectral data of Ceramide analog (39) 
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Ceramide analog; white solid: [α]25D -7.3˚ (c = 0.165, CHCl3); mp 73 ˚C;  IR vmax 3300, 
2916, 2849, 1642, 1615, 1547, 1466 cm-1; UV (CHCl3) λmax (log ε)  243 (0.3) nm; 1H 
NMR (CDCl3, 500 MHz) δ 6.24 (1H, d, J = 7.7 Hz, NH), 5.80 (1H, dt, J = 7.4, 15.5 Hz, 
H-5), 5.54 (1H, dt, J = 6.6, 15.6 Hz, H-4), 4.34 (1H, t, J = 5.0 Hz, H-3), 3.97 (1H, dd, J 
= 3.8, 11.0 Hz, H-1a), 3.71 (1H, dd, J = 3.3, 11.3 Hz, H-1b), 3.91 (1H, m, H-2), 2.24 
(2H, t, J = 7.5 Hz, H-2’), 2.02 (2H, m, H-6), 1.60 (2H, m, H-3’), 1.54 (1H, heptet, J = 
6.7 Hz, H-17), 1.40 (2H, m, H-7), 1.28 (16H, m, H – (8-15)), 1.28 (34H, m, H - (4’- 
23’)), 1.17 (2H, m, H-16), 0.90 (3H, t, J = 7.0 Hz, H-24’), 0.88 (3H, d, J = 6.8 Hz, H-
18), 0.88 (3H, d, J = 6.8 Hz, H-19); 13C NMR (CDCl3, 125 MHz) δ 174.5 (s, C-1’), 
134.2 (d, C-5), 129.19 (d, C-4), 74.2 (d, C-3), 62.4 (t, C-1), 54.9 (d, C-2), 39.8 (t, C-16), 
37.0 (t, C-2’), 32.6 (t, C-6), 29.9 (t, C8-15, C4’-23’), 28.2 (d, C-17), 27.9 (t, C-7), 26.0 
(t, C-3’), 22.9 (q, C-18), 22.8 (q, C-19), 14.3 (q, C-24’); LRFABMS m/z 664.5 [M + 
H]+, HRESIMS as C43H86NO3 (observed m/z 664.6599 [M + H]+, calculated for 
664.6607). 
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8.4.2 Methanolysis of Ceramide analog (39) 
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   Ceramide analog (39) (5 mg) was heated with 1.25 M HCl in MeOH (3 mL) at 70 ˚C 
for 20 h in 5 mL flask. The reaction mixture was extracted with petroleum ether, the 
extract concentrated in vacuo to give fatty acid methyl ester 40 (1.7 mg): 1H NMR 
(CDCl3, 500 MHz) δ 3.60 (3H, s, OCH3), 2.22 (2H, t, J = 6.5 Hz), 1.55 (2H, m), 1.18 
(br s), 0.81 (3H, t, J = 6.7 Hz); 13C NMR (CDCl3, 125 MHz) δ 174.5 (s), 51.7 (q, OCH3), 
34.4 (t), 32.2 (t), 29.9 (t), 29.8 (t), 29.7 (t), 29.6 (t), 29.5 (t), 29.4 (t), 25.2 (t), 22.9 (t), 
14.31 (q, CH3); LRFABMS m/z 383.3 [M + H]+, LREIMS m/z 382.5 [M]+, HREIMS as 
C25H50O2 (observed m/z 382.3804 [M]+, calculated 382.3811). 
 
    The MeOH layer was concentrated in vacuo to give a long chain base aminodiol (41) 
and then reacted with acetic anhydride in the presence of pyridine (1mL) overnight at 
room temperature. The reaction mixture was concentrated in vacuo to remove pyridine 
and diluted with CH2Cl2 (5 mL) with H2O (1 mL). The organic layer washed with 
saturated NaHCO3 solution, H2O, brine solution and then dried with anhydrous MgSO4. 
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The filtrate was concentrated in vacuo to give protected compound 42 and subjected to 
silica gel column chromatography using 40% EtOAc in hexane to give protected 
compound 42 (0.8 mg): 1H NMR (CDCl3, 500 MHz) δ 5.80 (1H, dt, J = 7.2, 14.8 Hz), 
5.65 (1H, J = 9.4 Hz, NH,), 5.40 (1H, dd, J = 7.6, 15.8 Hz), 5.28 (1H, t, J = 6.1 Hz), 
3.44 (1H, m), 4.31 (1H, dd, J = 6.2, 11.8 Hz), 4.05 (1H, dd, J = 3.8, 11.6 Hz), 2.08 (3H, 
s), 2.07 (3H, s), 2.04 (m), 1.99 (3H, s), 1.58 (br s), 1.52 (1H, m), 1.36 (2H, m), 1.26 (br 
s), 1.15 (2H, m), 0.87 (6H, d, 6.3 Hz); 13C NMR (CDCl3, 125 MHz) δ 171.2 (s), 170.2 
(s), 169.8 (s), 137.7 (d, CH), 124.4 (d, CH), 74.1 (d, CH), 62.8 (t), 50.9 (d, CH), 39.3 (t), 
32.5 (t), 29.9 (t), 29.8 (t), 29.6 (t), 29.4 (t), 29.1 (t), 28.2 (d, CH), 23.6 (q, acetoxy CH3), 
22.9 (q, isopropyl CH3), 22.9 (q, isopropyl CH3), 21.3 (q, acetoxy CH3), 21.1 (q, 
acetoxy CH3); LRFABMS m/z 440.3 [M + H]+, HRESIMS as C25H46NO5 (observed m/z 
440.3372 [M + H]+, calculated 440.3376). 
 
8.4.3 Preparation of MTPA esters for Ceramide analog (39) 
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8.4.3.1 (S) - MTPA Ester (43) 
       To a solution of ceramide analog (39) (1.5 mg) in pyridine (500 µL) was added 
(R)-MTPA-Cl (30 µL) at room temperature for 16 h and concentrated in vacuo. The 
residue was diluted with EtOAc (4mL)/H2O (1 mL) and then washed with saturated 
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NaHCO3 solution, H2O, brine solution and then dried with anhydrous MgSO4.   The 
filtrate was concentrated in vacuo and chromatographed on silica gel by EtOAc/hexane 
(5:95) to give (S) – MTPA ester (43) (0.7 mg) as colorless oil: [α]25D +60.0˚ (c = 0.015, 
CHCl3); 1H NMR (CDCl3, 500 MHz) δ 7.45 (10H, 2 MTPA’s aromatic protons), 5.81 
(1H, dt, J = 7.9, 13.4 Hz), 5.39 (1H, t, J = 7.8 Hz), 5.29 (1H, m), 5.27 (1H, d, J = 8.9 Hz,  
NH), 4.55 (1H, m), 4.39 (1H, dd, J = 5.2, 11.6 Hz), 4.34 (1H, dd, J = 4.0, 11.8 Hz), 3.53 
(3H, s), 3.48 (3H, s), 1.99 (m), 1.55 (br s), 1.49 (m), 1.26 (br s), 0.89 (3H, t, J = 6.8 Hz), 
0.87 (6H, d, J = 6.6 Hz). 
 
8.4.3.2 (R) - MTPA Ester (44) 
       Ceramide analog (39) (1.5 mg) was reacted with (S) – MTPA-Cl (30 µL) as 
described above and chromatographed to give (R) – MTPA ester (44) (0.3 mg) as 
colorless oil: [α]25D -29.0˚ (c = 0.0165, CHCl3); 1H NMR (CDCl3, 500 MHz) δ 7.46 
(10H, 2 MTPA’s aromatic protons), 5.90 (1H, dt, J = 5.5, 14.6 Hz), 5.42 (1H, t, J = 8.5 
Hz), 5.39 (1H, m), 5.23 (1H, d, J = 9.4 Hz,  NH), 4.49 (1H, m), 4.27 (1H, dd, J = 3.6, 
11.5 Hz), 4.20 (1H, dd, J = 5.6, 11.3 Hz), 3.53 (3H, s), 3.50 (3H, s), 2.02 (m), 1.56 (br 
s), 1.49 (m), 1.26 (br s), 1.15 (2H, m), 0.89 (3H, t, J = 6.8 Hz), 0.87 (6H, d, J = 6.6 Hz). 
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8.5 Synthesis of Erebusinone (12) 
 
8.5.1 Preparation of Benzyl-3-(benzyloxy)-2-nitrobenzoate (46) 
OBn
NO2
O
OBn
OH
NO2
O
OH K2CO3/BnBr
DMSO
95%
(45) (46)  
 
       To DMSO (100 ml) was added solid K2CO3, (9.05 g, 65.5 mmol, 6 eq.).   After 
stirring for 5 min, 3-hydroxy-2-nitrobenzoic acid (45) (2.0 g, 10.9 mmol, 1 eq.) was 
added all at once followed by benzylbromide (7.47g, 43.7 mmol, 4 eq.).   The reaction 
mixture was stirred at room temperature for 3 h and then poured into ice water (300 
mL).  After cooling, the solution was adjusted to pH 3-4 with HCl (10%) and extracted 
with CH2Cl2 (3 X 100 mL).  The organic layer washed with brine (2 X 50 mL), dried 
with MgSO4 and concentrated.  The residue was chromatographed on silica gel by 
EtOAc/hexane (5:95) to give 46 3.76g (95% yield) as a white solid: mp 82-83 ˚C;  IR 
vmax 3081, 2931, 1714, 1541, 1454, 1282 cm-1; UV (CHCl3) λmax (log ε)  243 (0.7), 303 
(0.44) nm; 1H NMR (CDCl3, 250 MHz) δ 7.61 (1H, d, J = 7.2 Hz), 7.38 (11H, m), 7.24 
(1H, d, J = 8.7 Hz), 5.34 (2H, s), 5.19 (2H, s); 13C NMR (CDCl3, 75 MHz) δ 162.7 (s), 
149.8 (s), 141.2 (s),134.9 (s), 134.7 (s), 130.5 (d), 128.7 (d), 128.6 (d), 128.3 (d), 126.9 
(d), 123.6 (s), 122.5 (d), 118.6 (d), 71.2 (t), 67.9 (t); HRESIMS [M + Na]+ m/z observed 
386.0998 (calculated for C21H17NO5Na  386.1005). 
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8.5.2 Preparation of 3-[3-(Benzyloxy)-2-nitrophenyl]-3-oxopropanenitrile (47) 
 
(47)(46)
OBn
NO2
O
OBn
OBn
NO2
O
CN
BuLi/CH3CN
THF/- 78 oC
90 %
 
       Anhydrous neat acetonitrile (1.06 g, 25.8 mmol, 2.5 eq) was added to a solution of 
n-butyllithium (1.99 g, 31.0 mmol, 3 eq) in THF (100 mL) at –78˚C.  After a white 
suspension formed, the solution of 46 (3.76g, 10.3 mmol, 1 eq) in THF (5 mL) was 
added into the reaction mixture.  The light brown reaction mixture was warmed to – 45 
˚C and then stirred for 2.5 h and the aqueous HCl (10%) was added until pH 4. The 
reaction mixture was concentrated in vacuo.  The residue was diluted with 
dichloromethane (300 mL) and then washed with water (2 X 50 mL) and brine (50 mL) 
and dried with MgSO4 and the solvent removed in vacuo. Flash chromatography eluting 
with EtOAc/hexane (from10:90 to 20:80) to afford 2.77 g (90% yield) of 47 as a brown 
solid: mp 160-161 ˚C; IR vmax 3081, 2931, 2220, 1708, 1544, 1449, 1285 cm-1; UV 
(CHCl3) λmax (log ε)  210 (1.21), 249 (0.30), 313 (0.13) nm; 1H NMR (CDCl3, 250 
MHz) δ 7.54 (1H, t, J = 8.3 Hz), 7.37 (6H, m), 7.26 (1H, d, J = 6.8 Hz), 5.26 (2H, s), 
4.00 (2H, s); 13C NMR (CDCl3, 75 MHz) δ 187.8 (s), 149.5 (s), 138.6 (s), 135.5 (d), 
131.7 (s), 128.6 (d), 128.3 (d), 127.5 (d), 126.9 (d), 122.3 (d), 120.8 (d), 115.1 (s), 70.7 
(t), 31.3 (t); HREIMS [M]+ m/z observed 296.0799 (calculated for C16H12N2O4  
296.0797). 
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8.5.3 Preparation of 3-[3-(Benzyloxy)-2-nitrophenyl]-3-hydroxypropanenitrile (48) 
 
(47) (48)
OBn
NO2
O
CN
NaBH4/H2O
MeOH
95 % OBn
NO2
OH
CN
 
 
         To a solution of 46 (300 mg, 1.0 mmol) in MeOH (10 mL) was added slowly a 
solution of NaBH4 (77 mg, 2.0 mmol), which was prepared with the solution (12 mL, 
4:1, methanol and H2O, pH 9) at 5 ˚C.  The reaction mixture was warmed to room 
temperature and stirred for 3 h.  The HCl (10%) solution was added to the reaction 
mixture until getting pH 4 and then concentrated in vacuo and diluted with EtOAc (100 
mL).  The organic layer was washed with brine and dried with MgSO4 and The residue 
was chromatographed on silica gel by EtOAc/hexane (10:90) to give 0.29g (95% yield) 
of 48 as a light brown solid: [α]25D 0˚ (c = 0.193, CHCl3); mp 72-73 ˚C; IR vmax 3389, 
2928, 2264, 1630, 1455, 1275 cm-1; UV (CHCl3) λmax (log ε)  244 (0.50) nm; 1H NMR 
(CDCl3, 250 MHz) δ 7.47 (1H, t, J =  8.1 Hz), 7.36 (7H, m), 7.08 (1H, d,  J =  8.1 Hz), 
5.15 (2H, s), 5.08 (1H, br s), 2.38 (2H, m); 13C NMR (CDCl3, 75 MHz) δ 149.6 (s), 
139.4 (s), 135.1 (s), 134.3 (s), 131.6 (d), 128.5 (d), 128.2 (d), 126.9 (d), 118.6 (d), 116.7 
(d), 114.1 (s), 71.0 (t), 65.1 (t), 27.2 (d); HRESIMS [M + Na]+ m/z observed 321.0841 
(calculated for C16H14N2O4Na  321.0852). 
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8.5.4 Preparation of 3-Amino-1-[3-(benzyloxy)-2-nitrophenyl]propan-1-ol (49) 
 
(49)(48)
OBn
NO2
OH
CN
THF
83 %
BH3S(CH3)2
OBn
NO2
OH
NH2
 
       To a solution of 48 (288 mg, 0.97 mmol) in THF (5 mL) was added BH3SMe2 (183 
mg, 2.41 mmol) in THF (10 mL) at 0 ˚C. The reaction mixture was refluxed for 3h and 
then cooled to room temperature. MeOH (2 mL) followed by 6 N HCl (2 mL) was 
added to reaction mixture and then refluxed again for additional 0.5h and cooled to 
room temperature and concentrated under reduced pressure. The residue was partitioned 
between EtOAc (50 mL) and 1N HCl solution (30 mL). The phases were separated and 
then aqueous layer was basified with 5 N NaOH and extracted with EtOAc (3 X 50 mL).    
The combined organic phases were dried with K2CO3 and concentrated under reduced 
pressure. The residue was chromatographed on silica gel by MeOH/CH2Cl2 (10:90) to 
give 292 mg (81% yield) of 49 as a pale brown solid: [α]25D 0˚ (c = 0.210, CHCl3); mp 
122-123 ˚C; IR vmax 3320, 3104, 2929,1608, 1525, 1455, 1273 cm-1; UV (CHCl3) λmax 
(log ε)  245 (0.5) nm; 1H NMR (CDCl3, 250 MHz) δ 7.23 (m, 7H), 6.85 (1H, d, J =  8.2 
Hz), 5.06 (2H, s), 4.80 (1H, d, J =  8.8 Hz), 3.03 (2H, m), 1.78 (2H, m); 13C NMR 
(CDCl3, 75 MHz) δ 149.2 (s), 139.8 (s), 137.9 (s), 135.5 (s), 130.8 (d), 128.5 (d), 128.1 
(d),126.9 (d), 119.1 (d), 112.5 (d), 70.8 (t), 70.5 (t), 39.9 (t), 38.5 (d); HREIMS [M]+ 
m/z observed 302.1261 (calculated for C16H18N2O4  302.1267). 
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8.5.5. Preparation of N-{3-[3-(Benzyloxy)-2-nitrophenyl]-3-hydroxypropyl} 
acetamide (50) 
 
(49)
OBn
NO2
OH
NH2
Ac2O
triethylamine
MeOH
82 %
(50)
OBn
NO2
OH
NHAc
 
      To a stirred solution of 49 (136 mg, 0.45 mmol) and triethylamine (68 mg, 0.68 
mmol, 1.5 eq) in CH2Cl2 (5 mL) was added Ac2O (55 mg, 0.54 mmol, 1.2 eq) at 0 ˚C. 
The reaction mixture was stirred at room temperature for overnight and then poured to 
dilute saturated NaHCO3 solution (5 mL) and the separated organic layer washed with 
brine and then dried with MgSO4 and concentrated. The residue was chromatographed 
on silica gel by MeOH/CH2Cl2 (1:99) to afford 127 mg (82% yield) of 50 as a pale 
brown solid: [α]25D 0˚ (c = 0.193, CHCl3); mp 102-103 ˚C; IR vmax 3425, 3264, 3097, 
1525, 1449 cm-1; UV (CHCl3) λmax (log ε)  243 (0.36) nm; 1H NMR (CDCl3, 250 MHz) 
δ 7.30 (6H, m), 7.18 (1H, d, J =  8.2 Hz), 6.93 (1H, d, J =  7.9 Hz), 5.93 (1H, br s), 5.14 
(2H, s), 4.68 (1H, dd,  J =  2.3, 9.2 Hz), 4.21 (1H, br s), 3.75 (1H, m), 3.10 (1H, m), 
1.99 (3H, s), 1.82 (2H, m); 13C NMR (CDCl3, 75 MHz) δ 171.8 (s), 149.3 (s), 139.9 (s), 
137.4 (s), 135.5 (s), 131.2 (d), 128.6 (d), 128.3 (d), 127.0 (d), 118.8 (d), 112.8 (d), 71.0 
(t), 66.5 (t), 38.8 (t), 36.4 (t), 23.0 (q); HRESIMS [M + H]+ m/z observed 345.1445 
(calculated for C18H21N2O5  345.1450), [M + Na]+ m/z observed 367.1268 (calculated 
for C18H20N2O5Na  367.1270). 
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8.5.6 Preparation of N-{3-[3-(benzyloxy)-2-nitrophenyl]-3-oxopropyl}acetamide 
(51) 
 
(51)(50)
OBn
NO2
OH
NHAc
OBn
NO2
O
NHAc
Dess Martin
oxidation
CH2Cl2
90%
 
 
          To a mixture of Dess-Martin periodinane (360 mg, 0.85 mmol, 3 eq) and pyridine 
(100 mg, 1.5 eq of Dess-Martin periodinane) in dichloromethane (3 mL) was added a 
solution of 50 (97 mg, 0.28 mmol) in dichloromethane (1.5 mL) at 0 ˚C and then stirred 
at room temperature for 2 h. The reaction mixture was diluted with saturated NaHCO3 
solution (6 mL) at 5 ˚C and the organic layer was separated and the aqueous layer was 
extracted with CH2Cl2. The combined organic extracts were washed with saturated 
Na2S2O3 (10 mL) and then water (2 X 10 mL) and brine and dried with MgSO4 and 
concentrated. The residue was chromatographed on silica gel by EtOAc/hexane (80:20) 
to give 88 mg (92% yield) of 51 as a white solid: mp 73-74 ˚C; IR vmax 3320, 3104, 
2929, 1608, 1525, 1455, 1273 cm-1; UV (CHCl3) λmax (log ε)  248 (1.1), 312 (0.47) nm; 
1H NMR (CDCl3, 250 MHz) δ 7.43 (1H, t, J = 8.1 Hz), 7.23 (m, 6H), 7.22 (1H, d, J = 
8.1 Hz), 5.17 (2H, s), 3.54 (2H, q, J = 5.6 Hz), 3.14 (2H, t,  J = 5.7 Hz), 1.90 (3H,s); 13C 
NMR (CDCl3, 75 MHz) δ 197.7 (s), 170.4 (s), 150.3 (s), 139.3 (s), 134.8 (s), 131.2 (s), 
130.7 (d), 128.7 (s), 128.4 (s), 126.9 (s), 120.6 (s), 118.6 (s), 71.3 (t), 39.7 (t), 34.1 (t), 
23.1 (q); HREIMS [M]+ m/z observed 342.1222 (calculated for C18H18N2O5  342.1216). 
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8.5.7. Preparation of Erebusinone, N-[3-(2-amino-3-hydroxyphenyl)-3-oxopropyl] 
acetamide (12) 
(51)
OBn
NO2
O
NHAc
Erebusinone (12)
H2, Pd/C, 1 atm
EtOH
93% OH
NH2
O
NHAc
 
 
         A mixture of 51 (30 mg, 0.09 mmol) and 10 % Pd/C (15 mg) in dried ethanol (15 
mL) was shaken with hydrogen atmosphere (1 atm) for 3 h. The reaction mixture was 
filtered to remove the catalyst and then concentrated. The residue was chromatographed 
on silica gel by MeOH/CH2Cl2 (2:98) to give 18.2 mg (93% yield) of erebusinone (12) 
as a bright yellow solid: mp 150-151 ˚C; IR vmax 3488, 3362, 2925, 1619, 1568, 1458, 
1221 cm-1; UV (MeOH) λmax (log ε)  231 (3.2), 272 (1.5), 375 (1.1) nm; 1H NMR 
(MeOH-d4, 250 MHz) δ 7.28 (1H, dd, J = 8.3, 1.0 Hz), 6.79 (1H, dd J = 7.6, 1.2 Hz), 
6.45 (1H, t, J = 7.9 Hz), 3.40 (2H, t,  J = 6.5 Hz), 3.12 (2H, t, J = 6.5 Hz), 1.9 (3H, s); 
13C NMR (MeOH-d4, 75 MHz) δ 201.2 (s), 173.5 (s), 146.4 (s), 142.4 (s), 122.8 (s), 
118.9 (d), 118.0 (d), 115.8 (d), 39.6 (t), 36.5 (t), 22.7 (q); HREIMS [M]+ m/z observed 
222.1007 (calculated for C11H14N2O3  222.1004). 
 
 
 
 
 106
8.6  Synthesis of Erebusinonamine (52) 
 
8.6.1 Preparation of tert-Butyl 3-[3-(benzyloxy)-2-nitrophenyl]-3-
hydroxypropylcarbamate (53) 
 
(49)
OBn
NO2
OH
N
H
OBn
NO2
OH
NH2
t-BOC2O
triethylamine
MeOH
100%
O
OC(CH3)3
(53)
 
        To a stirred solution of 42 (2.0 g, 66.15 mmol) and triethylamine (0.67 g, 66.20 
mmol, 1 eq) in MeOH (100 mL) was added di-tert-butyldicarbonate (2.17 g, 99.20 
mmol, 1.5 eq) in MeOH (20 mL) at 0 ˚C. The reaction mixture was stirred at room 
temperature for 3 h and then concentrated. The crude mixture was diluted with CH2Cl2 
(50 mL) and washed with saturated NaHCO3 solution (2 X 15 mL) and the separated 
organic layer washed with brine and then dried with MgSO4 and concentrated to give 
2.66 g (100% yield) of 45 as a pale yellow oil which was directly used in the next step 
without purification: [α]25D 0˚ (c = 0.140, CHCl3); IR vmax 3416, 2979, 1686, 1609, 1532, 
1368, 1278, 1069 cm-1; UV (MeOH) λmax (log ε)  224 (3.5) nm; 1H NMR (CDCl3, 250 
MHz) δ 7.30 (m, 6H), 7.20 (1H, d, J = 8.0 Hz), 6.93 (1H, d, J = 8.4 Hz), 5.13 (2H, s), 
4.88 (1H, br s), 4.72 (1H, d, J = 8.8 Hz), 3.53 (1H, m), 3.07 (1H, m), 1.79 (2H, m), 1.42 
(9H, s); 13C NMR (CDCl3, 75 MHz) δ 157.0 (s), 148.9 (s), 139.6 (s), 136.9 (s), 135.1 (s), 
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130.7 (d), 128.2 (d), 127.7 (d), 126.6 (s), 118.4 (s), 112.4 (s), 79.6 (s), 70.6 (t), 65.8 (d), 
39.0 (t), 36.6 (t), 27.8 (q). 
 
8.6.2. Preparation of tert-butyl-3-[3-(benzyloxy)-2-nitrophenyl]-3-oxopropyl- 
carbamate (54) 
 
(54)(53)OBn
NO2
OH
N
H
O
OC(CH3)3
OBn
NO2
O
N
H
O
OC(CH3)3
Dess Martin
oxidation
CH2Cl2
80 %
 
        To a mixture of Dess-Martin periodinane (5.27g, 124 mmol, 2 eq.) and pyridine 
(1.97g, 248 mmol, 2.0 eq of Dess-Martin periodinane) in CH2Cl2 (60 mL) was added a 
solution of 53 (97 mg, 0.28 mmol) in CH2Cl2 (30 mL) at 0˚C and then stirred at room 
temperature for 2h.  The reaction mixture was diluted with saturated NaHCO3 solution 
(60 mL) at 5 ˚C and the organic layer was separated and the aqueous layer was extracted 
with CH2Cl2.  The combined organic extracts were washed with saturated Na2S2O3 (60 
mL) and then H2O (2 X 30 mL) and brine and dried with MgSO4 and concentrated.  The 
residue was chromatographed on silica gel by EtOAc/hexane (80:20) to give 1.98 g 
(80%) of 54 as a white solid: mp 66-67 ˚C; IR vmax 3355, 2977, 2928, 1681, 1568, 1514, 
1221 cm-1; UV (CHCl3) λmax (log ε)  247 (1.0), 313 (0.4) nm; 1H NMR (CDCl3, 250 
MHz) δ 7.44 (1H, t, J = 8.1 Hz), 7.23 (6H, m), 7.16 (1H, d,  J = 7.7 Hz), 5.17 (2H, s), 
3.45 (2H, q, J = 5.8 Hz), 3.10 (2H, t, J = 5.5 Hz), 1.39 (9H, s); 13C NMR (CDCl3, 75 
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MHz) δ 196.9 (s), 155.5 (s), 149.9 (s), 138.9 (s), 134.5 (s), 130.7 (s), 130.3 (d), 128.3 
(d), 128.0 (d), 126.5 (d), 120.3 (d), 118.2 (d), 78.9 (s), 70.8 (t), 39.7 (t), 34.8 (t), 27.9 
(q); HRESIMS [M + Na]+ m/z observed 423.1535 (calculated for C21H24N2O6Na  
423.1532), [M + K]+ m/z observed 439.1271 (calculated for C21H24N2O6K  439.1271). 
 
 
8.6.3 Preparation of 3-amino-1-[3-(benzyloxy)-2-nitrophenyl]propan-1-one 
hydrochloride (55) 
(54) (55)OBn
NO2
O
N
H
1.25 M HCl
MeOH
100%
O
OC(CH3)3
OBn
NO2
O
NH3Cl
 
        To a mixture of t-BOC protected compound 54 (0.2g, 0.5 mmol) in MeOH (2 mL) 
was added HCl solution (7 mL, 1.25 M in MeOH) at 0 ˚C and then stirred at room 
temperature for 24 h.  The reaction mixture was concentrated to give 168 mg (100% 
yield) of 55 as a white solid which was directly used without any purification for the 
next step: mp 169-170 ˚C; IR vmax 2957, 2856, 1693, 1539, 1284 cm-1; UV (MeOH) λmax 
(log ε)  213 (1.1), 250 (0.2), 313 (0.1) nm; 1H NMR (MeOH-d4, 250 MHz) δ 7.59 (3H, 
m), 7.35 (5H, m), 5.22 (2H, s), 3.44 (2H, m), 3.27 (2H, m); 13C NMR (MeOH-d4, 75 
MHz) δ 196.8 (s), 151.5 (s), 140.6 (s), 136.9 (s), 136.9 (s), 132.6 (d), 130.5 (d), 129.6 
(d), 129.3 (d), 128.4 (d), 122.5 (d), 120.9 (d), 72.3 (t), 37.9 (t), 35.5 (t); HRESIMS [M - 
Cl]+ m/z observed 301.1187 (calculated for C16H17N2O4  301.1188). 
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8.6.4 Preparation of erebusinonamine, 3-amino-1-[2-amino-3-hydroxyphenyl]- 
propan-1-one hydrochloride (52) 
 
(55)
OBn
NO2
O
NH3Cl
Erebusinonamine (52)
H2, Pd on C, 3.5 atm
MeOH
90%
OH
NH2
O
NH3Cl
 
 
         A mixture of precursor of erebusinonamine (55) (66 mg, 0.2 mmol) and 10 % 
Pd/C (120 mg) in MeOH (50 mL) was shaken with hydrogen atmosphere (3.5 atm) for 
overnight. The reaction mixture was filtered to remove the catalyst and then 
concentrated. The residue was chromatographed on silica gel by eluting with 
MeOH/CH2Cl2/CF3COOH (20:80:0.1) to give 42.5 mg (89.5% yield) of  
erebusinonamine (52) as a brown wet solid: IR vmax 3200, 2925, 1671, 1184 cm-1; UV 
(MeOH) λmax (log ε)  235 (0.6), 273 (0.2), 381 (0.1) nm; 1H NMR (MeOH-d4, 250 
MHz) δ 7.18 (1H, d,  J = 8.8 Hz), 6.77 (1H, d,  J = 7.6 Hz), 6.50 (t, 1H, J = 8.2 Hz), 
3.23 (4H, m); 13C NMR (MeOH-d4, 75 MHz) δ 200.04 (s), 146.9 (s),122.0 (d), 119.3 (s), 
118.4 (s),117.4 (d), 114.2 (d), 35.6 (t), 35.1.(t); HRESIMS [M - Cl]+ m/z observed 
181.0969 (calculated for C9H13N2O2  181.0977). 
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Figure 69. UV spectrum of purine analog (23) in MeOH. 
 
Figure 70. IR spectrum of purine analog (23). 
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Figure 71. DEPT-135 spectrum of  purine analog (23) (125 MHz, DMSO-d6). 
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Figure 72. gCOSY spectrum of purine analog (23) (500 MHz, DMSO-d6). 
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Figure 73. UV spectrum of 3-hydroxykynurenine (24) in MeOH. 
 
Figure 74. IR spectrum of 3-hydroxykynurenine (24). 
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Figure 75. gCOSY spectrum of 3-hydroxykynurenine (24) (500 MHz, DMSO-d6). 
 
Figure 76.  DEPT-135 spectrum of 3-hydroxkynurenine (24) (125 MHz, DMSO-d6). 
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Figure 77. gHSQC spectrum of 3-hydroxykynurenine (24) (500 MHz, DMSO-d6). 
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Figure 78. gHMBC spectrum of 3-hydroxykynurenine (24) (500 MHz, DMSO-d6). 
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Figure 79. UV spectrum of 5-methyl-2’-deoxycytidine (25) in MeOH. 
 
 
 
 
 
 
Figure 80. IR spectrum of 5-methyl-2’-deoxycytidine (25). 
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 Figure 81.  gCOSY spectrum of 5-methyl-2’-deoxycytidine (25) (500 MHz, MeOH-d4). 
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Figure 82.  ROESY spectrum of 5-methyl-2’-deoxycytidine (25) (500 MHz, MeOH-d4). 
 
 
Figure 83. DEPT-135 spectrum of 5-methyl-2’-deoxycytidine (25) (125 MHz, MeOH-d4). 
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 Figure 84. gHSQC spectrum of 5-methyl-2’-deoxycytidine (25) (500 MHz, MeOH-d4). 
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Figure 85. gHMBC spectrum of 5-methyl-2’-deoxycytidine (25) (500 MHz, MeOH-d4). 
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Figure 86. UV spectrum of uridine (28) in MeOH. 
 
 
Figure 87. IR spectrum of uridine (28). 
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Figure 88. DEPT-135 spectrum of uridine (28) (125 MHz, DMSO-d6). 
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Figure 89. ROESY spectrum of uridine (28) (500 MHz, DMSO-d6). 
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Figure 90. gCOSY spectrum of uridine (28) (500 MHz, DMSO-d6). 
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Figure 91. gHSQC spectrum of uridine (28) (500 MHz, DMSO-d6). 
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Figure 92. gHMBC spectrum of uridine (28) (500 MHz, DMSO-d6). 
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Figure 93. UV spectrum of 2-deoxycytidine (31) in MeOH. 
 
Figure 94. IR spectrum of 2-deoxycytidine (31). 
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Figure 95. DEPT-135 spectrum of 2-deoxycytidine (31) (125 MHz, DMSO-d6). 
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Figure 96. ROESY spectrum of 2-deoxycytidine (31) (500 MHz, DMSO-d6). 
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Figure 97. gCOSY spectrum of 2-deoxycytidine (31) (500 MHz, DMSO-d6). 
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Figure 98. gHSQC spectrum of 2-deoxycytidine (31) (500 MHz, DMSO-d6). 
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Figure 99. gHMBC spectrum of 2-deoxycytidine (31) (500 MHz, DMSO-d6). 
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Figure 100. UV spectrum of 4, 8-dihydroxyquinoline (33) in MeOH. 
 
Figure 101. IR spectrum of 4, 8-dihydroxyquinoline (33). 
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Figure 102. DEPT-135 spectrum of 4, 8-dihydroxyquinoline (33) (125 MHz, DMSO-d6). 
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Figure 103. ROESY spectrum of 4, 8-dihydroxyquinoline (33) (500 MHz, DMSO-d6). 
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Figure 104. gCOSY spectrum of 4, 8-dihydroxyquinoline (33) (500 MHz, DMSO-d6). 
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Figure 105. gHSQC spectrum of 4, 8-dihydroxyquinoline (33) (500 MHz, DMSO-d6). 
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Figure 106. UV spectrum of homarine (37) in MeOH. 
 
 
 
Figure 107. IR spectrum of homarine (37). 
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Figure 108. DEPT-135 spectrum of homarine (37) (125 MHz, DMSO-d6). 
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Figure 109. ROESY spectrum of homarine (37) (500 MHz, DMSO-d6). 
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Figure 110. gCOSY spectrum of homarine (37) (500 MHz, DMSO-d6).  
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Figure 111. gHSQC spectrum of homarine (37) (500 MHz, DMSO-d6). 
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Figure 112. UV spectrum of ceramide analog (39) in CHCl3. 
 
 
 
 
Figure 113. IR spectrum of ceramide analog (39). 
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 Figure 114. gCOSY spectrum of ceramide analog (39) (500 MHz, CDCl3). 
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 Figure 115. TOCSY spectrum of ceramide (39) (500 MHz, CDCl3). 
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Figure 116.  DEPT-45 spectrum of ceramide analog (39) (125 MHz, CDCl3). 
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 Figure 117.  gHSQC spectrum of ceramide analog (39) (500 MHz, CDCl3). 
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Figure 118.  gHMBC spectrum of ceramide analog (39) (500 MHz, CDCl3). 
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 Figure 119.  NOESY spectrum of ceramide analog (39) (500 MHz, CDCl3). 
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 Figure 120. gCOSY spectrum of (S)-MTPA ester (43) (500 MHz, CDCl3). 
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 Figure 121. gCOSY spectrum of (R)-MTPA ester (44) (500 MHz, CDCl3). 
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Figure 122. UV spectrum of benzyl-3-(benzyloxy)-2-nitrobenzoate (46) in CHCl3.
 
 
Figure 123. IR spectrum of benzyl-3-(benzyloxy)-2-nitrobenzoate (46). 
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Figure 124. 1H NMR spectrum of benzyl-3-(benzyloxy)-2-nitrobenzoate (46)  
(250 MHz, CDCl3). 
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Figure 125. 13C NMR spectrum of benzyl-3-(benzyloxy)-2-nitrobenzoate (46)  
(75 MHz, CDCl3). 
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Figure 126. UV spectrum of 3-[3-(benzyloxy)-2-nitrophenyl]-3-oxopropanenitrile (47) 
in CHCl3. 
 
 
Figure 127. IR spectrum of 3-[3-(benzyloxy)-2-nitrophenyl]-3-oxopropanenitrile (47). 
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Figure 128. 1H NMR spectrum of 3-[3-(benzyloxy)-2-nitrophenyl]-3-oxopropanenitrile 
(47) (250 MHz, CDCl3). 
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Figure 129. 13C NMR spectrum of 3-[3-(benzyloxy)-2-nitrophenyl]-3-oxopropanenitrile 
(47) (250 MHz, CDCl3). 
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Figure 130. UV spectrum of 3-[3-(benzyloxy)-2-nitrophenyl]-3-hydroxypropanenitrile 
(48) in CHCl3. 
 
 
Figure 131. IR spectrum of 3-[3-(benzyloxy)-2-nitrophenyl]-3-hydroxypropanenitrile (48).  
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Figure 132. 1H NMR spectrum of 3-[3-(benzyloxy)-2-nitrophenyl]-3-
hydroxypropanenitrile (48) (250 MHz, CDCl3). 
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Figure 133. 13C NMR spectrum of 3-[3-(benzyloxy)-2-nitrophenyl]-3-
hydroxypropanenitrile (48) (75 MHz, CDCl3). 
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Figure 134. UV spectrum of 3-amino-1-[3-(benzyloxy)-2-nitrophenyl]propan-1-ol (49) 
in CHCl3. 
 
 
Figure 135. IR spectrum of 3-amino-1-[3-(benzyloxy)-2-nitrophenyl]propan-1-ol (49).  
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Figure 136. 1H NMR spectrum of 3-amino-1-[3-(benzyloxy)-2-nitrophenyl]propan-1-ol 
(49) (250 MHz, CDCl3). 
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Figure 137. 13C NMR spectrum of 3-amino-1-[3-(benzyloxy)-2-nitrophenyl]propan-1-ol 
(49) (75 MHz, CDCl3). 
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Figure 138. UV spectrum of N-{3-[3-(benzyloxy)-2-nitrophenyl]-3-
hydroxypropyl}acetamide (50) in CHCl3. 
 
Figure 139. IR spectrum of N-{3-[3-(benzyloxy)-2-nitrophenyl]-3-
hydroxypropyl}acetamide (50). 
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Figure 140. 1H NMR spectrum of N-{3-[3-(benzyloxy)-2-nitrophenyl]-3-
hydroxypropyl}acetamide (50) (250 MHz, CDCl3). 
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Figure 141. 13C NMR spectrum of N-{3-[3-(benzyloxy)-2-nitrophenyl]-3-
hydroxypropyl}acetamide (50) (75 MHz, CDCl3). 
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Figure 142. UV spectrum of N-{3-[3-(benzyloxy)-2-nitrophenyl]-3-
oxoypropyl}acetamide (51) in CHCl3. 
 
 
Figure 143. IR spectrum of N-{3-[3-(benzyloxy)-2-nitrophenyl]-3-oxopropyl}acetamide (51). 
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Figure 144. 1H NMR spectrum of N-{3-[3-(benzyloxy)-2-nitrophenyl]-3-
oxoypropyl}acetamide (51) (250 MHz, CDCl3). 
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Figure 145. 13C NMR spectrum of N-{3-[3-(benzyloxy)-2-nitrophenyl]-3-
oxoypropyl}acetamide (51) (75 MHz, CDCl3). 
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Figure 146. UV spectrum of erebusinone (12) in MeOH. 
 
 
Figure 147. IR spectrum of erebusinone (12).
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Figure 148. 1H NMR spectrum of erebusinone (12) (250 MHz, MeOH-d4). 
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Figure 149. 13C NMR spectrum of erebusinone (12) (75 MHz, MeOH-d4). 
 
 177
224.9700317,
3.567027092
-0.5
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
200 250 300 350 400 450 500
 
Figure 150. UV spectrum of tert-butyl-3-[3-(benzyloxy)-2-nitrophenyl]-3-
hydroxypropylcarbamate (53).  
 
Figure 151. IR spectrum of tert-butyl-3-[3-(benzyloxy)-2-nitrophenyl]-3-
hydroxypropylcarbamate (53).  
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Figure 152. 1H NMR spectrum of tert-butyl-3-[3-(benzyloxy)-2-nitrophenyl]-3-
hydroxypropylcarbamate (53) (250 MHz, CDCl3). 
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Figure 153. 13C NMR spectrum of tert-butyl-3-[3-(benzyloxy)-2-nitrophenyl]-3-
hydroxypropylcarbamate (53) (75 MHz, CDCl3). 
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Figure 154. UV spectrum of tert-butyl-3-[3-(benzyloxy)-2-nitrophenyl]-3-
oxopropylcarbamate (54) in CHCl3. 
 
 
Figure 155. IR spectrum of tert-butyl-3-[3-(benzyloxy)-2-nitrophenyl]-3-
oxopropylcarbamate (54).
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Figure 156.  1H NMR spectrum of tert-butyl-3-[3-(benzyloxy)-2-nitrophenyl]-3-
oxopropylcarbamate (54) (250 MHz, CDCl3). 
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Figure 157.  13C NMR spectrum of tert-butyl-3-[3-(benzyloxy)-2-nitrophenyl]-3-
oxopropylcarbamate (54) (75 MHz, CDCl3). 
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Figure 158. UV spectrum of 3-amino-1-[3-(benzyloxy)-2-nitrophenyl]propan-1-one 
hydrochloride (55) in MeOH. 
 
 
Figure 159. IR spectrum of 3-amino-1-[3-(benzyloxy)-2-nitrophenyl]propan-1-one 
hydrochloride (55).
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Figure 160. 1H NMR spectrum of 3-amino-1-[3-(benzyloxy)-2-nitrophenyl]propan-1-
one hydrochloride (55) (250 MHz, MeOH-d4).
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Figure 161. 13C NMR spectrum of 3-amino-1-[3-(benzyloxy)-2-nitrophenyl]propan-1-
one hydrochloride (55) (75 MHz, MeOH-d4).
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Figure 162. UV spectrum of erebusinonamine (52) in MeOH. 
 
 
Figure 163. IR spectrum of erebusinonamine (52). 
 187
   7.204
  7.174
  7.172
  6.790
  6.788
  6.760
  6.757
  6.531
  6.500
  6.469
  5.038
  3.305
  3.274
  3.253
  3.199
  3.179
8
7
6
5
4
3
2
1
0PP
M
Figure 164. 1H NMR spectrum of erebusinonamine (52) (250 MHz, MeOH-d4).
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Figure 165. 13C NMR spectrum of erebusinonamine (52) (75 MHz, MeOH-d4).
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Figure 166. DEPT-135 spectrum of erebusinonamine (52) (125 MHz, MeOH-d4). 
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